[{"isHealthy":false,"overview":"Overview\tThe Test Case document is comprised of  three tabs.\nOverview\nOverview\tThe first tab is this tab (Overview) and is merely a high-level tab to orient the user in regards to the other tabs.  It should not be used to infer, interpret, or assume any logic or values.\nOverview\nOverview\tThe second tab is the test case layout tab which describes the layout of the test cases on the third and final tab.\nOverview\nOverview\tThe third tab are the test cases with one test case per row.  All test cases in this file focus on patients who have an underlying condition which would result in an immunity, contraindication, or indication.\n\nResources\tRecommended Immunization Schedule for Persons Aged 0 through 18 years - http://www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html\nResources\tRecommended Immunization Schedule for Adults Age 19 Years and Older - Recommended Immunization Schedule for Adults Age 19 Years and Older - http://www.cdc.gov/vaccines/schedules/hcp/adult.html\nResources\tGeneral Recs – MMWR/ January 28, 2011 / Vol. 60 / No. 2 - http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6002a1.htm\nResources\tIIS Standard Code Sets - http://www.cdc.gov/vaccines/programs/iis/code-sets.html\nResources\tCOVID-19 - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html\nResources\tDTaP - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/dtap.html\nResources\tHep A - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hepa.html\nResources\tHep B - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hepb.html\nResources\tHib - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hib.html\nResources\tHPV - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hpv.html\nResources\tInfluenza - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html\nResources\tJapanese Encephalitis - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/je.html\nResources\tMeasles Mumps and Rubella - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mmr.html\nResources\tMeningococcal - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/mening.html\nResources\tPneumococcal - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/pneumo.html\nResources\tPolio - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/polio.html\nResources\tRotavirus - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/rotavirus.html\nResources\tTdap/Td - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/tdap-td.html\nResources\tTyphoid - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/typhoid.html\nResources\tVaricella - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/varicella.html\nResources\tYellow Fever - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/yf.html\nResources\tZoster - http://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/shingles.html\n","testCaseLayout":"Column\tField Name\tDescription\nA\tCDC_Test_ID\tSimple numerical identifier for the test case.\nB\tTest_Case_Name\tHuman-readable test name to briefly describe the test case.\nC\tDOB\tDate of birth of the patient. DOB format: MM/DD/YYYY (e.g., 01/01/2000).\nD\tGender\tGender of the patient. Either M or F (Male or Female)\nE\tObservation_Code_1\tObservation Code is the CDSi defined coded value based on ACIP language.  See Supporting Data file \"ScheduleSupportingData - Coded Observations.xlsx\" for the full list.\nF\tObservation_Text_1\tObservation text is the human readable text associated with the code in the previous column.\nG\tObservation_Date_1\tObservation Date is the date associated with the observation.\nH – M\tObservations 2 and 3\tObservations 2 and 3.  This is a repitition of fields E - G.\nN\tSeries_Status\tSeries Status is the measure of the patients status in relationship to presumed immunity.\nO\tDate_Administered_1\tDate vaccine dose was administered. Date format: MM/DD/YYYY (e.g., 01/01/2000).\nP\tVaccine_Name_1\tHuman readable trade name or the unspecified formulation of the vaccine.\nQ\tCVX_1\tCoded value to define the type of vaccine. Together with MVX the trade name can be inferred.\nR\tMVX_1\tCoded value to define the manufacturer of the vaccine. Together with CVX the trade name can be inferred. If an unspecified formulation is used, no MVX is specified.\nS\tEvaluation_Status_1\tExpected evaluation status (Valid, Not Valid, Extraneous) of the vaccine dose administered based on the ACIP recommendations. In the case of a combination shot, the Expected Evaluation Status is related to the Vaccine Group targeted by the particular test case. The other components of the combination vaccine are tested in their respective Vaccine Group test cases.\nT\tSeries_Type_1\tProvides the Series Type (Standard or Risk) where the Evaluation Status was determined.\nU\tEvaluation_Reason_1\tProvides further information as to why the dose administered was not valid. In the case of a combination shot, the reason is related to the Vaccine Group targeted by the particular test case. The other components of the combination vaccine are tested in their specific Vaccine Group test cases.\nV - BK\tVaccine Doses Administered 2 through 7.  This is a repetition of fields O-U\tVaccine Doses Administered 2 through 7. This is a repetition of fields O-U\nBL\tForecast_#\tTarget Dose being forecasted. If Target Doses 1 and 2 have been satisfied, the Target Dose Number being forecasted would be Target Dose Number 3. If the patient no longer requires a dose (complete, immune, contraindication), the forecast_# is set to “-“.\nBM\tEarliest_Date\tEarliest point in time which the next vaccine dose could be administered and still be considered valid. This does not include the 4-day grace period. Date format: MM/DD/YYYY (e.g., 01/01/2000).\nBN\tRecommended_Date\tDate at which the next vaccine dose administered should be given. Date format: MM/DD/YYYY (e.g., 01/01/2000).\nBO\tPast_Due_Date\tDate at which the patient is considered overdue for their immunization. Date format: MM/DD/YYYY (e.g., 01/01/2000).\nBP\tAdministrative_Guidance\tAdministrative Guidance is used to provide additional - usual non-computable or overly complex ACIP language - information to the clinician to aid in decision making.\nBQ\tVaccine_Group\tThe Vaccine Group being tested with the test case.\nBR\tAssessment Date\tAssessment Date is the date which should be used during evaluation and forecasting rather than the current date.  This is used to help with test cases which would become invalid over time.\nBS\tEvaluation_Test_Type\tEvaluation Test Type is used to categorize the test case.  This will allow testers to focus in on categories of tests as needed.\nBT\tDate_Added\tThis is the date the test case was created. The format is MM/DD/YYYY. (e.g.: 01/01/2000)\nBU\tDate Updated\tThis is the date the test case was changed. The format is MM/DD/YYYY. (e.g.: 01/01/2000)\nBV\tForecast_Test_Type\tForecast Test Type is used to categorize the test case.  This will allow testers to focus on categories of tests as needed.\nBW\tReason_For_Change\tAs test cases are changed, this field is used to document the reason the test case was changed.\nBX\tChanged_In_Version\tThis field documents the version number the test case was last changed.\n","cases":"CDC_Test_ID\tTest_Case_Name\tDOB\tGender\tObservation_Code_1\tObservation_Text_1\tObservation_Date_1\tObservation_Code_2\tObservation_Text_2\tObservation_Date_2\tObservation_Code_3\tObservation_Text_3\tObservation_Date_3\tSeries_Status\tDate_Administered_1\tVaccine_Name_1\tCVX_1\tMVX_1\tEvaluation_Status_1\tSeries_Type_1\tEvaluation_Reason_1\tDate_Administered_2\tVaccine_Name_2\tCVX_2\tMVX_2\tEvaluation_Status_2\tSeries_Type_2\tEvaluation_Reason_2\tDate_Administered_3\tVaccine_Name_3\tCVX_3\tMVX_3\tEvaluation_Status_3\tSeries_Type_3\tEvaluation_Reason_3\tDate_Administered_4\tVaccine_Name_4\tCVX_4\tMVX_4\tEvaluation_Status_4\tSeries_Type_4\tEvaluation_Reason_4\tDate_Administered_5\tVaccine_Name_5\tCVX_5\tMVX_5\tEvaluation_Status_5\tSeries_Type_5\tEvaluation_Reason_5\tDate_Administered_6\tVaccine_Name_6\tCVX_6\tMVX_6\tEvaluation_Status_6\tSeries_Type_6\tEvaluation_Reason_6\tDate_Administered_7\tVaccine_Name_7\tCVX_7\tMVX_7\tEvaluation_Status_7\tSeries_Type_7\tEvaluation_Reason_7\tForecast_#\tEarliest_Date\tRecommended_Date\tPast_Due_Date\tAdministrative_Guidance\tVaccine_Group\tAssessment_Date\tEvaluation_Test_Type\tDate_added\tDate_updated\tForecast_Test_Type\tReason_For_Change\tChanged_In_Version\n2015-UC-0012\tVaricella: Zoster dose administered at 50 years - 1 day\t23891\tF\t055\tHealth care personnel\t\t\t\t\t\t\t\tNot Complete\t42152\tZostavax\t121\t\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t42180\t42180\t42207\t\tVAR\t42152\tVaccine: Off Label\t43000\t43808\tRecommended based on interval\tupdated test case title and description.\t4.1\n2016-UC-0002\tAnaphylaxis to previous dose\t40461\tF\t080\tAdverse reaction to vaccine component\t\t\t\t\t\t\t\tContraindicated\t40522\tDTaP Unspecified\t107\t\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tDTaP\t40522\tAll Valid: Forecast Test\t41275\t43545\tNot recommended: contraindication\tAdded description\t4.0\n2016-UC-0003\tEncephalopathy within 7 days of Pediarix. \t40576\tF\t079\tEncephalopathy not attributable to another identifiable cause within 7 days of administration of a previous dose of Tdap, DTP, or DTaP vaccine\t\t\t\t\t\t\t\tNot Complete\t40635\tPEDIARIX\t110\tSKB\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t40663\t40696\t40753\t\tDTaP\t40635\tAll Valid: Forecast Test\t41275\t43545\tRecommended based on age\tAdded description\t4.0\n2016-UC-0004\tAnaphylaxis to previous dose of Pediarix\t40461\tF\t080\tAdverse reaction to vaccine component\t\t\t\t\t\t\t\tContraindicated\t40527\tPEDIARIX\t110\tSKB\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tDTaP\t40527\tAll Valid: Forecast Test\t41275\t43545\tNot recommended: contraindication\tAdded description\t4.0\n2016-UC-0005\tAnaphylaxis to previous dose of Pentacel\t40335\tF\t080\tAdverse reaction to vaccine component\t\t\t\t\t\t\t\tContraindicated\t40392\tPENTACEL\t120\tPMC\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tDTaP\t40392\tAll Valid: Forecast Test\t41275\t43545\tNot recommended: contraindication\tAdded description\t4.0\n2016-UC-0006\tAnaphylaxis following previous dose of Influenza\t41459\tF\t085\tSevere allergic reaction after previous dose of Influenza\t\t\t\t\t\t\t\tContraindicated\t41920\tInfluenza Unspecified\t88\t\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tFlu\t41920\tAll Valid: Forecast Test\t41275\t43545\tNot recommended: contraindication\tAdded description\t4.0\n2016-UC-0007\tAnaphylaxis to previous dose of Hep A.  No forecast. \t37683\tF\t096\tSevere allergic reaction after previous dose of Hepatitis A\t\t\t\t\t\t\t\tContraindicated\t39876\tHep A Unspecified\t85\t\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tHepA\t39876\tAll Valid: Forecast Test\t41275\t43545\tNot recommended: contraindication\tAdded description\t4.0\n2016-UC-0008\tAnaphylaxis to previous dose of Hep B.  No further forecast. \t38969\tF\t097\tSevere allergic reaction after previous dose of Hepatitis B\t\t\t\t\t\t\t\tContraindicated\t39032\tRECOMBIVAX-PEDS\t08\tMSD\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tHepB\t39032\tAll Valid: Forecast Test\t41275\t43545\tNot recommended: contraindication\tAdded description\t4.0\n2016-UC-0009\tAnaphylaxis to previous dose of Pentacel (Hib)\t40335\tF\t080\tAdverse reaction to vaccine component\t\t\t\t\t\t\t\tContraindicated\t40392\tPENTACEL\t120\tPMC\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tHib\t40392\tAll Valid: Forecast Test\t41275\t43545\tNot recommended: contraindication\tAdded description\t4.0\n2016-UC-0010\tAnaphylaxis to previous dose of HPV Vaccine\t36665\tF\t090\tSevere allergic reaction after previous dose of HPV\t\t\t\t\t\t\t\tContraindicated\t40713\tHPV Unspecified\t137\t\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tHPV\t40713\tAll Valid: Forecast Test\t41275\t43545\tNot recommended: contraindication\tAdded description\t4.0\n2016-UC-0011\tAnaphylaxis to previous dose of MCV\t36582\tF\t095\tSevere allergic reaction after previous dose of Meningococcal\t\t\t\t\t\t\t\tContraindicated\t40617\tMeningococcal MCV4 Unspecified\t147\t\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tMeningococcal\t40617\tAll Valid: Forecast Test\t41275\t43545\tNot recommended: contraindication\tAdded description\t4.0\n2016-UC-0012\tAnaphylactic reaction to dose 1 of MMR.  No forecast for additional dose. \t40403\tF\t091\tSevere allergic reaction after previous dose of Measles\t\t\t\t\t\t\t\tContraindicated\t40788\tM-M-R II\t03\tMSD\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tMMR\t40788\tAll Valid: Forecast Test\t41275\t43546\tNot recommended: contraindication\tAdded description\t4.0\n2016-UC-0013\tDiagnosis of severe immunodeficiency.  No forecast for MMR. \t40796\tF\t154\tHIV/AIDS - severely immunocompromised\t\t\t\t\t\t\t\tContraindicated\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tMMR\t40796\tNo Doses Administered\t41275\t43546\tNot recommended: contraindication\tUpdated Observation code to  154 and added description.\t4.0\n2016-UC-0014\tAnaphylaxis to previous dose of PCV7.  No forecast. \t39274\tF\t094\tSevere allergic reaction after previous dose of Pneumococcal\t\t\t\t\t\t\t\tContraindicated\t39336\tPREVNAR 7\t100\tWAL\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tPneumococcal\t39336\tAll Valid: Forecast Test\t41275\t43546\tNot recommended: contraindication\tAdded description\t4.0\n2016-UC-0015\tAnaphylaxis to previous dose.  No forecast. \t40748\tF\t081\tSevere allergic reaction after previous dose of Polio\t\t108\tSevere allergic reaction to streptomycin\t\t\t\t\tContraindicated\t40810\tIPOL\t10\tPMC\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tPOL\t40810\tAll Valid: Forecast Test\t41275\t43546\tNot recommended: contraindication\tAdded description\t4.0\n2016-UC-0016\tSevere combined immunodeficiency (SCID)=no rotavirus vaccine\t40940\tF\t013\tSevere Combined Immunodeficiency [SCID]\t\t\t\t\t\t\t\tContraindicated\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tRota\t40982\tNo Doses Administered\t41275\t43675\tNot recommended: contraindication\tUpdated assessment date\t4.0\n2016-UC-0017\tAnaphylaxis following previous dose\t40940\tF\t083\tSevere allergic reaction after previous dose of Rotavirus\t\t\t\t\t\t\t\tContraindicated\t41000\tROTARIX\t119\tSKB\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tRota\t41000\tAll Valid: Forecast Test\t41275\t43546\tNot recommended: contraindication\tAdded description\t4.0\n2016-UC-0018\tAnaphylaxis following previous dose\t40940\tF\t083\tSevere allergic reaction after previous dose of Rotavirus\t\t\t\t\t\t\t\tContraindicated\t41000\tROTATEQ\t116\tMSD\tValid\tstandard\t\t41030\tROTARIX\t119\tSKB\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tRota\t41030\tAll Valid: Forecast Test\t41275\t43546\tNot recommended: contraindication\tAdded description\t4.0\n2016-UC-0019\tHistory of VZ\t38108\tF\t024\tHealthcare provider verified history of or diagnosis of Varicella\t38443\t\t\t\t\t\t\tImmune\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tVAR\t38443\tNo Doses Administered\t41275\t43546\tNot recommended: immune\tAdded description\t4.0\n2016-UC-0020\tTiter of immunity to VZ=series complete or exempt\t38504\tF\t024\tHealthcare provider verified history of or diagnosis of Varicella\t\t\t\t\t\t\t\tImmune\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tVAR\t38869\tNo Doses Administered\t41275\t43675\tNot recommended: immune\tUpdated assessment date\t4.0\n2016-UC-0021\tAnaphylactic reaction to dose 1 of VZ\t40524\tF\t089\tSevere allergic reaction after previous dose of Varicella\t\t\t\t\t\t\t\tContraindicated\t40983\tVARIVAX\t21\tMSD\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tVAR\t40983\tAll Valid: Forecast Test\t41275\t43546\tNot recommended: contraindication\tAdded description\t4.0\n2016-UC-0022\tDiagnosis of severe immunodeficiency.  No second dose. \t40159\tF\t154\tHIV/AIDS - severely immunocompromised\t\t\t\t\t\t\t\tContraindicated\t40532\tVARIVAX\t21\tMSD\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tVAR\t40532\tAll Valid: Forecast Test\t41275\t43546\tNot recommended: contraindication\tUpdated observation code to 154 and added description\t4.0\n2016-UC-0023\tDiagnosis of severe immunodeficiency before administration of any VZ. No VZ to be given. \t40500\tF\t154\tHIV/AIDS - severely immunocompromised\t\t\t\t\t\t\t\tContraindicated\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tVAR\t40865\tNo Doses Administered\t41275\t43675\tNot recommended: contraindication\tUpdated assessment date\t4.0\n2016-UC-0024\tVaricella: Patient has laboratory evidence of immunity for Varicella\t33040\tF\t023\tLaboratory Evidence of Immunity or confirmation of Varicella disease\t\t\t\t\t\t\t\tImmune\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tVAR\t33405\tNo Doses Administered\t42178\t43675\tNot recommended: immune\tUpdated assessment date\t4.0\n2016-UC-0025\tVaricella: Patient has a Varicella verifiable diagnosis by a healthcare provider.\t30483\tF\t024\tHealthcare provider verified history of or diagnosis of Varicella\t\t\t\t\t\t\t\tImmune\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tVAR\t38154\tNo Doses Administered\t42178\t43675\tNot recommended: immune\tUpdated assessment date\t4.0\n2016-UC-0026\tVaricella: Patient has a Herpes Zoster verifiable diagnosis by a healthcare provider.\t26469\tF\t024\tHealthcare provider verified history of or diagnosis of Varicella\t\t\t\t\t\t\t\tImmune\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tVAR\t42174\tNo Doses Administered\t42178\t43675\tNot recommended: immune\tUpdated assessment date\t4.0\n2016-UC-0027\tVaricella: Patient is a healthcare worker with a one-dose history of  Varicella vaccine.\t24925\tF\t055\tHealth care personnel\t\t\t\t\t\t\t\tNot Complete\t42152\tVARIVAX\t21\tMSD\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t42180\t42180\t42207\t\tVAR\t42152\tAll Valid: Forecast Test\t42178\t43546\tRecommended based on interval\tAdded description and Updated past due date  \t4.0\n2016-UC-0028\tVaricella: Patient is a healthcare worker with evidence of immunity for Varicella.\t24978\tM\t055\tHealth care personnel\t\t\t\t\t\t\t\tComplete\t41093\tVARIVAX\t21\tMSD\tValid\tstandard\t\t41121\tVarivax\t21\t\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tVAR\t41121\tAll Valid: Forecast Test\t42178\t43675\tRecommended based on interval\tUpdated assessment date\t4.0\n2016-UC-0029\tVaricella: Patient is pregnant, and has not been found to have evidence of immunity for Varicella.\t28295\tF\t007\tPregnant\t\t\t\t\t\t\t\tContraindicated\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tVAR\t42174\tNo Doses Administered\t42178\t43675\tNot recommended: contraindication\tUpdated assessment date\t4.0\n2016-UC-0031\tZoster Live Vaccine: Anaphylactic reaction to Zoster vaccine components (Gelatin or neomycin)\t20256\tF\t107\tSevere allergic reaction to neomycin\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t38519\t38519\t\t\tZoster\t42171\tNo Doses Administered\t42178\t43546\tRecommended based on Condition\tUpdated to reflect that RZV can be used instead of ZVL.  The use of the new product removes the test cases from being Contraindicated. Added description\t4.0\n2016-UC-0032\tMMR: Patient is a healthcare worker, born before 1957, has received one dose of the MMR vaccine.\t20313\tF\t055\tHealth care personnel\t\t\t\t\t\t\t\tNot Complete\t42124\tM-M-R II\t03\tMSD\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t42152\t42152\t44343\t\tMMR\t42124\tAll Valid: Forecast Test\t42178\t43804\tRecommended based on interval\tV4.1 added past due date v 4.0 Updated to reflect that if a patient is a healthcare worker and has received one dose of the MMR vaccine that a second dose should be administered 4 weeks later. Added description.\t4.1\n2016-UC-0033\tPatient is 31 years of age, vaccine naive, and seeking protection from Hep A\t31138\tM\t001\tPatient seeks protection\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t31503\t31503\t31895\t\tHepA\t42483\tNo Doses Administered\t42583\t43675\tRecommended based on Condition\tUpdated to display accurate forecasting dates, assessment date, and added description.\t4.0\n2016-UC-0034\tPatient is an adult seeking protection  from Hepatitis A, and has received the first dose  of the risk 2 dose series.\t28637\tM\t001\tPatient seeks protection\t\t\t\t\t\t\t\tNot Complete\t42552\tHep A, adult\t52\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t42736\t42736\t\t\tHepA\t42552\tAll Valid: Forecast Test\t42583\t43547\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0035\tPatient is an adult seeking protection from Hepatitis A, and has received the second dose of the Hep A risk 2- dose series.\t33314\tF\t001\tPatient seeks protection\t\t\t\t\t\t\t\tComplete\t42491\tHep A, adult\t52\tMSD\tValid\trisk\t\t42675\tHep A, adult\t52\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tHepA\t42675\tAll Valid: Forecast Test\t42583\t43547\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0036\tPatient is 55 years of age, has chronic liver disease, and has not received Hepatitis A vaccine.\t22383\tF\t015\tChronic liver disease\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t22748\t22748\t23140\t\tHepA\t42583\tNo Doses Administered\t42583\t43675\tRecommended based on Condition\tUpdated Past Due date, assessment date, and added description\t4.0\n2016-UC-0037\tPatient has Chronic liver disease and has received the first dose of the Hep A risk Twinrix 3 dose series .\t22383\tF\t015\tChronic liver disease\t\t\t\t\t\t\t\tNot Complete\t42583\tHepA-HepB\t104\tSKB\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t42611\t42611\t\t\tHepA\t42583\tAll Valid: Forecast Test\t42583\t43547\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0038\tPatient has Chronic liver disease and has received the second dose of the Hep A risk Twinrix 3 dose series .\t24518\tM\t015\tChronic liver disease\t\t\t\t\t\t\t\tNot Complete\t42461\tHepA-HepB\t104\tSKB\tValid\trisk\t\t42489\tHepA-HepB\t104\tSKB\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t42644\t42644\t\t\tHepA\t42489\tAll Valid: Forecast Test\t42583\t43607\tRecommended based on Condition\tUpdated to reflect the recommended interval of 5 months for dose #3. and added description\t4.0\n2016-UC-0039\tPatient has Chronic liver disease and has received all three doses of the Hep A risk Twinrix 3 dose series .\t24313\tM\t015\tChronic liver disease\t\t\t\t\t\t\t\tComplete\t42587\tHep A\t104\tSKB\tValid\trisk\t\t42615\tHepA-HepB\t104\tSKB\tValid\trisk\t\t42770\tHepA-HepB\t104\tSKB\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tHepA\t42770\tAll Valid: Forecast Test\t42583\t43607\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0040\tPatient is a Public safety worker exposed to blood or infectious body fluids and has not received the Hepatitis B vaccine.\t21927\tM\t057\tPublic safety worker exposed to blood or infection body fluids\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t43842\t43842\t\t\tHepB\t44639\tNo Doses Administered\t42591\t44648\tRecommended based on Condition\tUpdated test case date of birth and assessment date based on 2022 MMWR for HepB.\t4.4\n2016-UC-0042\tPatient is a Public Safety worker and has received the first and second dose of the Twinrix 4 dose series.\t21927\tM\t057\tPublic safety worker exposed to blood or infection body fluids\t\t\t\t\t\t\t\tNot Complete\t44622\tHep B\t104\tSKB\tValid\trisk\t\t44629\tHep B\t104\tSKB\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t44643\t44643\t44651\t\tHepB\t44629\tAll Valid: Forecast Test\t42591\t44648\tRecommended based on interval\tUpdated test case date of birth, date administered dates, and assessment date based on 2022 MMWR for HepB.\t4.4\n2016-UC-0043\tPatient is a Public Safety worker and has received the third dose of the Twinrix 4 dose series.\t21927\tM\t057\tPublic safety worker exposed to blood or infection body fluids\t\t\t\t\t\t\t\tNot Complete\t44622\tHep B\t104\tSKB\tValid\trisk\t\t44629\tHep B\t104\tSKB\tValid\trisk\t\t44643\tHep B\t104\tSKB\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t4\t44987\t44987\t\t\tHepB\t44643\tAll Valid: Forecast Test\t42591\t44648\tRecommended based on interval\tUpdated test case date of birth, date administered dates, earliest and recommended dates, and assessment date based on 2022 MMWR for HepB.\t4.4\n2016-UC-0044\tPatient is  a Public safety worker exposed to blood or infectious body fluids and has received all four doses of the accelerated Twinrix 4 dose vaccine series.\t21927\tM\t057\tPublic safety worker exposed to blood or infection body fluids\t\t\t\t\t\t\t\tComplete\t44257\tHep B\t104\tSKB\tValid\trisk\t\t44264\tHep B\t104\tSKB\tValid\trisk\t\t44278\tHep B\t104\tSKB\tValid\trisk\t\t44622\tHep B, Adult \t104\tSKB\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tHepB\t44622\tAll Valid: Forecast Test\t42591\t44648\tNot Recommended: Series Complete\tUpdated test case date of birth, date administered dates, and assessment date based on 2022 MMWR for HepB.\t4.4\n2016-UC-0045\tPatient is on dialysis, and has not received any doses of the Hep B vaccine.\t32159\tM\t032\tDialysis patient\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t39464\t39464\t\t\tHepB\t44248\tNo Doses Administered\t42604\t44648\tRecommended based on Condition\tUpdated test case  age and assessment date based on 2022 MMWR for HepB.\t4.4\n2016-UC-0046\tPatient is on dialysis and has received the first dose of the Hep B risk Recombivax 3 dose series vaccine.\t32159\tM\t032\tDialysis patient\t\t\t\t\t\t\t\tNot Complete\t44248\tHep B, Dialysis\t44\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t44276\t44276\t\t\tHepB\t44248\tAll Valid: Forecast Test\t42604\t44648\tRecommended based on interval\tUpdated test case  age and assessment date based on 2022 MMWR for HepB.\t4.4\n2016-UC-0047\tPatient is on dialysis and has received the second dose of the Hep B risk Recombivax 3 dose series vaccine.\t32159\tM\t032\tDialysis patient\t\t\t\t\t\t\t\tNot Complete\t44248\tHep B, Dialysis\t44\tMSD\tValid\trisk\t\t44276\tHep B, Dialysis\t44\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t44360\t44429\t\t\tHepB\t44276\tAll Valid: Forecast Test\t42604\t44648\tRecommended based on interval\tUpdated test case  DOB and first and second dose and assessment dates based on 2022 MMWR for HepB.\t4.4\n2016-UC-0048\tPatient is on dialysis, and has received all three doses of the Hep B risk Recombivax 3 dose series vaccine.\t32159\tM\t032\tDialysis patient\t\t\t\t\t\t\t\tNot Complete\t44248\tHep B, Dialysis\t44\tMSD\tValid\trisk\t\t44276\tHep B, Dialysis\t44\tMSD\tValid\trisk\t\t44429\tHep B, Dialysis\t44\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t4\t44794\t44794\t\t\tHepB\t44429\tAll Valid: Forecast Test\t42604\t44683\tRecommended based on interval\tUpdated test case  DOB and all three doses including forecast for booster dose,  assessment dates based on 2022 MMWR for HepB.\t4.4\n2016-UC-0050\tPatient is on dialysis and has received the first dose of the Hep  B risk Engerix- B 4- dose series.\t17211\tF\t032\tDialysis patient\t\t\t\t\t\t\t\tNot Complete\t44531\tHep B, Adult \t43\tSKB\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t44559\t44559\t\t\tHepB\t44531\tAll Valid: Forecast Test\t42608\t44683\tRecommended based on interval\tUpdated the first dose date, earliest and Recommended dates. Also updated the assessment date, date updated and general descriptions to align more with current recommendations for Hep B.\t4.4\n2016-UC-0051\tPatient is on dialysis, and has received the second dose of the Hep  B risk Engerix- B 4- dose series.\t17211\tF\t032\tDialysis patient\t\t\t\t\t\t\t\tNot Complete\t44531\tHep B, Adult \t43\tSKB\tValid\trisk\t\t44559\tHep B, Adult \t43\tSKB\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t44587\t44587\t\t\tHepB\t44559\tAll Valid: Forecast Test\t42608\t44683\tRecommended based on interval\tUpdated the first dose date, earliest and Recommended dates. Also updated the assessment date, date updated and general descriptions to align more with current recommendations for Hep B.\t4.4\n2016-UC-0052\tPatient is on dialysis, and has received the third dose of the Hep  B risk Engerix- B 4- dose series.\t17211\tF\t032\tDialysis patient\t\t\t\t\t\t\t\tNot Complete\t44531\tHep B, Adult \t43\tSKB\tValid\trisk\t\t44559\tHep B, Adult \t43\tSKB\tValid\trisk\t\t44587\tHep B, Adult \t43\tSKB\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t4\t44643\t44713\t\t\tHepB\t44587\tAll Valid: Forecast Test\t42608\t44683\tRecommended based on interval\tUpdated the first second and third dose date, earliest and Recommended dates. Also updated the assessment date, date updated and general descriptions to align more with current recommendations for Hep B.\t4.4\n2016-UC-0053\tPatient is on dialysis and has received all four doses of the Hep  B risk Engerix- B 4- dose series.\t17211\tF\t032\tDialysis patient\t\t\t\t\t\t\t\tNot Complete\t44531\tHep B, Adult \t43\tSKB\tValid\trisk\t\t44559\tHep B, Adult \t43\tSKB\tValid\trisk\t\t44587\tHep B, Adult \t43\tSKB\tValid\trisk\t\t44707\tHep B, Adult \t43\tSKB\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t5\t45072\t45072\t\t\tHepB\t44707\tAll Valid: Forecast Test\t42608\t44684\tRecommended based on interval\tUpdated the first second and third dose date, earliest and Recommended dates. Also updated the assessment date, date updated and general descriptions to align more with current recommendations for Hep B.\t4.4\n2016-UC-0054\tPatient is 2 years of age, has anatomical or functional asplenia, and has not received any prior doses of the Hib vaccine. \t41835\tF\t160\tAnatomical or functional asplenia\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t42200\t42200\t\t\tHib\t42200\tNo Doses Administered\t42593\t43675\tRecommended based on Condition\tAdded description, updated assessment date\t4.0\n2016-UC-0055\tPatient is 2 years of age and has anatomical or functional asplenia and has received one dose of the Hib Risk 2 dose series vaccine.\t41835\tF\t160\tAnatomical or functional asplenia\t\t\t\t\t\t\t\tNot Complete\t42597\tPRP-T\t48\tPMC\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t42653\t42653\t\t\tHib\t42597\tAll Valid: Forecast Test\t42593\t43675\tRecommended based on Condition\tAdded description, updated assessment date\t4.0\n2016-UC-0056\tPatient is 2 years of age and has anatomical or functional asplenia and has received the second dose of the Hib Risk 2 dose series.\t41835\tF\t160\tAnatomical or functional asplenia\t\t\t\t\t\t\t\tComplete\t42590\tPRP-T\t48\tPMC\tValid\tstandard\t\t42646\tPRP-T\t48\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tHib\t42646\tAll Valid: Forecast Test\t42593\t43472\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0057\tPatient is 18 months of age, has Persistent complement, properdin, or factor B deficiency and has received only one dose of the Hib vaccine before 12 months of age.\t41861\tF\t151\tPersistent complement, properdin, or factor B deficiency\t\t\t\t\t\t\t\tNot Complete\t42014\tPRP-OMP\t49\tMSD\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t42226\t42226\t\t\tHib\t42014\tAll Valid: Forecast Test\t42607\t43675\tRecommended based on Condition\tAdded description, updated assessment date\t4.0\n2016-UC-0058\tPatient is a child that has Persistent complement, properdin, or factor B deficiency and has received  one dose of the Hib standard vaccine before 12 months of age, and one dose of the Hib risk child 2 dose series vaccine.\t41861\tF\t151\tPersistent complement, properdin, or factor B deficiency\t\t\t\t\t\t\t\tNot Complete\t42014\tPRP-OMP\t49\tMSD\tValid\tstandard\t\t42473\tPRP-OMP\t49\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t42529\t42529\t\t\tHib\t42473\tAll Valid: Forecast Test\t42607\t43589\tRecommended based on Condition\tUpdated to display accurate forecasting date based on ACIP recommendations, added description\t4.0\n2016-UC-0059\tPatient is a child that has Persistent complement, properdin, or factor B deficiency and has received  one dose of the Hib standard vaccine before 12 months of age, and two doses of the Hib risk child 2 dose series vaccine.\t41861\tF\t151\tPersistent complement, properdin, or factor B deficiency\t\t\t\t\t\t\t\tComplete\t42014\tPRP-OMP\t49\tMSD\tValid\tstandard\t\t42473\tPRP-OMP\t49\tMSD\tValid\trisk\t\t42529\tPRP-OMP\t49\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tHib\t42529\tAll Valid: Forecast Test\t42607\t43580\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0060\tPatient is 36 months of age, has anatomical or functional asplenia and has received two  dose of the Standard Hib vaccine before 12 months of age.\t41386\tM\t160\tAnatomical or functional asplenia\t\t\t\t\t\t\t\tNot Complete\t41435\tPRP-T\t48\tPMC\tValid\tstandard\t\t41463\tPRP-T\t48\tPMC\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t41519\t41519\t\t\tHib\t41463\tAll Valid: Forecast Test\t42593\t43472\tRecommended based on Condition\tUpdated to display accurate forecasting date based on ACIP recommendations\t4.0\n2016-UC-0061\tPatient is 36 months of age, has anatomical or functional asplenia and has received two previous doses of the Standard Hib vaccine before 12 months of age and a dose of the Hib risk child 2 dose series vaccine.\t41386\tM\t160\tAnatomical or functional asplenia\t\t\t\t\t\t\t\tComplete\t41435\tPRP-T\t48\tPMC\tValid\tstandard\t\t41463\tPRP-T\t48\tPMC\tValid\tstandard\t\t42504\tPRP-T\t48\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tHib\t42504\tAll Valid: Forecast Test\t42593\t43580\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0062\tPatient is 7 years of age, has not received any Hib vaccine, and is undergoing elective splenectomy.\t39986\tM\t002\tUndergoing elective splenectomy\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t40443\t40443\t\tVaccination 14 or more days before splenectomy is suggested.\tHib\t42552\tNo Doses Administered\t42597\t43801\tRecommended based on Condition\tUpdated earliest and recommended forecast dates  to age 15 mos based on childhood recommendations for undergoing elective splenectomy and added description.\t4.1\n2016-UC-0063\tPatient is 7 years and is undergoing elective splenectomy and has received the one dose Hib risk 1 dose series\t39986\tM\t002\tUndergoing elective splenectomy\t\t\t\t\t\t\t\tComplete\t42552\tPRP-OMP\t49\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\tVaccination 14 or more days before splenectomy is suggested.\tHib\t42552\tAll Valid: Forecast Test\t42597\t43472\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0064\tPatient is 19 years of age is undergoing elective splenectomy and has no history of receiving Hib vaccine \t35621\tF\t002\tUndergoing elective splenectomy\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t36078\t36078\t\tVaccination 14 or more days before splenectomy is suggested.\tHib\t42585\tNo Doses Administered\t42597\t43801\tRecommended based on Condition\tUpdated Earliest and Recommended date to reflect 15 mos, Added description, updated assessment date\t4.1\n2016-UC-0065\tPatient is 19 years of age and undergoing elective splenectomy and has received the Hib risk 1 dose series\t35621\tF\t002\tUndergoing elective splenectomy\t\t\t\t\t\t\t\tComplete\t42585\tPRP-OMP\t49\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\tVaccination 14 or more days before splenectomy is suggested.\tHib\t42585\tAll Valid: Forecast Test\t42597\t43473\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0066\tPatient is 12 years of age, has HIV infection, and unvaccinated with Hib vaccine\t37734\tF\t186\tHIV Infection\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t38191\t38191\t\t\tHib\t42403\tNo Doses Administered\t42605\t44231\tRecommended based on Condition\t4.2: Updated observation code from 155 to 186.\t4.2\n2016-UC-0067\tPatient is 12 years of age, has HIV infection, and has received the Hib risk 1 dose series.\t37734\tF\t186\tHIV Infection\t\t\t\t\t\t\t\tComplete\t42403\tPRP-OMP\t49\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tHib\t42403\tAll Valid: Forecast Test\t42605\t44231\tRecommended based on Condition\t4.2: Updated observation code from 155 to 186.\t4.2\n2016-UC-0068\tPatient is 4 years of age, a recipient of a successful hematopoietic stem cell transplant 6 months ago and has not received a dose of the Hib vaccine.\t40404\tM\t004\tRecipient of a hematopoietic stem cell transplant\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t40446\t40446\t\tAt least 4 weeks should separate doses, 6 to 12 months after a successful transplant.\tHib\t41901\tNo Doses Administered\t42597\t43473\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0069\tPatient is a child that is a recipient of a successful hematopoietic stem cell transplant and has received a dose of the Hib vaccine.\t40404\tM\t004\tRecipient of a hematopoietic stem cell transplant\t\t\t\t\t\t\t\tNot Complete\t41901\tPRP-T\t48\tPMC\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t41929\t41929\t\tAt least 4 weeks should separate doses, 6 to 12 months after a successful transplant.\tHib\t41901\tAll Valid: Forecast Test\t42597\t43473\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0070\tPatient is a child and  a recipient of a successful hematopoietic stem cell transplant and has received two doses of  the Hib risk 3-dose series.\t38816\tM\t004\tRecipient of a hematopoietic stem cell transplant\t\t\t\t\t\t\t\tNot Complete\t41901\tPRP-T\t48\tPMC\tValid\tstandard\t\t41929\tPRP-T\t48\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t41957\t41957\t\tAt least 4 weeks should separate doses, 6 to 12 months after a successful transplant.\tHib\t41929\tAll Valid: Forecast Test\t42597\t43473\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0071\tPatient is a child is a recipient of a successful hematopoietic stem cell transplant, and has received all three doses of the Hib risk 3 dose series 6 to 12 months post operation. \t38135\tM\t004\tRecipient of a hematopoietic stem cell transplant\t\t\t\t\t\t\t\tComplete\t41791\tPRP-T\t48\tPMC\tValid\tstandard\t\t41819\tPRP-T\t48\tPMC\tValid\trisk\t\t41847\tPRP-T\t48\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\tAt least 4 weeks should separate doses, 6 to 12 months after a successful transplant.\tHib\t41847\tAll Valid: Forecast Test\t42597\t43473\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0072\tPatient is 20 years of age and is a recipient of a successful hematopoietic stem cell transplant and has not receive any recommended doses of the Hib vaccine.\t35198\tM\t004\tRecipient of a hematopoietic stem cell transplant\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t35240\t35240\t\tAt least 4 weeks should separate doses, 6 to 12 months after a successful transplant.\tHib\t42578\tNo Doses Administered\t42604\t43474\tRecommended based on Condition\tAdded Vaccine Group, Descriptions, and forecast date\t4.0\n2016-UC-0073\tPatient is an adult recipient of a successful hematopoietic stem cell transplant, and has received the first dose of the Hib Risk 3 dose series.\t35198\tM\t004\tRecipient of a hematopoietic stem cell transplant\t\t\t\t\t\t\t\tNot Complete\t42576\tPRP-T\t48\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t42604\t42604\t\tAt least 4 weeks should separate doses, 6 to 12 months after a successful transplant.\tHib\t42576\tAll Valid: Forecast Test\t42604\t43474\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0074\tPatient is a adult recipient of a successful hematopoietic stem cell transplant, and has received the second dose of the Hib Risk 3 dose series.\t35198\tM\t004\tRecipient of a hematopoietic stem cell transplant\t\t\t\t\t\t\t\tNot Complete\t42576\tPRP-T\t48\tPMC\tValid\trisk\t\t42604\tPRP-T\t48\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t42632\t42632\t\tAt least 4 weeks should separate doses, 6 to 12 months after a successful transplant.\tHib\t42604\tAll Valid: Forecast Test\t42607\t43474\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0075\tPatient is a adult recipient of a successful hematopoietic stem cell transplant, and has received all three doses of the Hib Risk 3 dose series.\t35198\tM\t004\tRecipient of a hematopoietic stem cell transplant\t\t\t\t\t\t\t\tComplete\t42576\tPRP-T\t48\tPMC\tValid\trisk\t\t42604\tPRP-T\t48\tPMC\tValid\trisk\t\t42632\tPRP-T\t48\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\tAt least 4 weeks should separate doses, 6 to 12 months after a successful transplant.\tHib\t42632\tAll Valid: Forecast Test\t42607\t43474\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0076\tPatient is 9 years of age, female, has a history of sexual abuse/assault and has not received the HPV vaccine.\t39176\tF\t169\tHistory of sexual abuse or assault\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t42464\t42464\t43193\t\tHPV\t42744\tNo Doses Administered\t42597\t43607\tRecommended based on Condition\t added Past Due date, and description\t4.0\n2016-UC-0077\tPatient is a 9 years of age, female, has a history of sexual abuse/assault, and has received the first dose of the HPV vaccine.\t39176\tF\t169\tHistory of sexual abuse or assault\t\t\t\t\t\t\t\tNot Complete\t42719\t9vHPV\t165\tMSD\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t42870\t42901\t43142\t\tHPV\t42719\tAll Valid: Forecast Test\t42597\t43607\tRecommended based on Condition\t added description\t4.0\n2016-UC-0078\tPatient is 10 years of age, female, has a history of sexual abuse/assault, and has received the second dose of the HPV risk female 2 dose series at 5 months.\t38898\tF\t169\tHistory of sexual abuse or assault\t\t\t\t\t\t\t\tComplete\t42587\t9vHPV\t165\tMSD\tValid\tstandard\t\t42740\t9vHPV\t165\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tHPV\t42740\tAll Valid: Forecast Test\t42598\t43589\tNot Recommended: Patient Complete\t added description\t4.0\n2016-UC-0079\tPatient is 11 years of age, female, has a history of sexual abuse/assault, and has received two doses  of the HPV risk female 2 dose series\t38414\tF\t169\tHistory of sexual abuse or assault\t\t\t\t\t\t\t\tComplete\t42723\t9vHPV\t165\tMSD\tValid\tstandard\t\t42887\t9vHPV\t165\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tHPV\t42887\tAll Valid: Forecast Test\t42598\t43474\tRecommended based on Condition\tNew HPV 2 dose recommendation, added description\t4.0\n2016-UC-0080\tPatient is 9 years of age, male, has a history of sexual abuse/assault, and has not received the HPV vaccine.\t39128\tM\t169\tHistory of sexual abuse or assault\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t42415\t42415\t43145\t\tHPV\t42691\tNo Doses Administered\t42598\t43628\tRecommended based on Condition\t added description\t4.0\n2016-UC-0083\tPatient is 10 years of age, male, has a history of T-Lymphocyte , and has received three doses of the HPV risk male 3 dose series vaccine.\t38789\tM\t148\tT-lymphocyte [cell-mediated and humoral] - Partial defects\t\t\t\t\t\t\t\tComplete\t42507\t9vHPV\t165\tMSD\tValid\tstandard\t\t42535\t9vHPV\t165\tMSD\tValid\trisk\t\t42675\t9vHPV\t165\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tHPV\t42675\tAll Valid: Forecast Test\t42599\t43474\tRecommended based on Condition\tUpdate test case with observational code 148. Added description.\t4.0\n2016-UC-0084\tPatient is 9 years of age, male, has a history of sexual abuse/assault, and has received the 2nd dose of the Risk Male 2 dose HPV vaccine at 4 weeks.\t39095\tM\t169\tHistory of sexual abuse or assault\t\t\t\t\t\t\t\tNot Complete\t42481\t9vHPV\t165\tMSD\tValid\tstandard\t\t42509\t9vHPV\t165\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t42634\t42664\t42903\t\tHPV\t42509\tAll Valid: Forecast Test\t42599\t43589\tRecommended based on Condition\t added description\t4.0\n2016-UC-0085\tPatient is an adult male,  MSM, and has no previous history of the HPV vaccine.\t34367\tM\t036\tMen who have sex with men\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t37654\t38385\t39142\t\tHPV\t42402\tAll Valid: Forecast Test\t42599\t43474\tRecommended based on Condition\tUpdated Earliest, Recommended, and Past due dates, added description\t4.0\n2016-UC-0086\tPatient is an adult male, MSM, and has received his first dose of the HPV vaccine.\t34367\tM\t036\tMen who have sex with men\t\t\t\t\t\t\t\tNot Complete\t42572\t9vHPV\t165\tMSD\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t42600\t42600\t42683\t\tHPV\t42572\tAll Valid: Forecast Test\t42599\t43474\tRecommended based on Condition\tUpdated Earliest, Recommended, Past due dates, and added description.\t4.0\n2016-UC-0087\tPatient is an adult male, MSM, and has received the second dose of the HPV risk adult male 3 dose series.\t32165\tM\t036\tMen who have sex with men\t\t\t\t\t\t\t\tNot Complete\t41732\t4vHPV \t062\tMSD\tValid\tstandard\t\t41760\t4vHPV \t062\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t41885\t41915\t41973\t\tHPV\t41760\tAll Valid: Forecast Test\t42600\t43474\tRecommended based on Condition\tUpdated Earliest, Recommended, and past due date based on HPV Recommendations, added description\t4.0\n2016-UC-0088\tPatient is an adult male, MSM, and has received all three doses of the HPV risk adult male 3-dose series.\t32933\tM\t036\tMen who have sex with men\t\t\t\t\t\t\t\tComplete\t42091\t4vHPV \t062\tMSD\tValid\tstandard\t\t42119\t4vHPV \t062\tMSD\tValid\trisk\t\t42261\t4vHPV \t62\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tHPV\t42261\tAll Valid: Forecast Test\t42600\t43474\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0089\tPatient is 32 years of age and plans on traveling to an endemic area (for longer than a month) with Japanese encephalitis.\t30864\tF\t165\tLonger-term (e.g., 1 month or more) travel to a JE-endemic area\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t30926\t30926\t\tACIP recommends that if the primary series of JE-VC was administered greater than 1 year previously, a booster dose may be given before potential JE virus exposure. ACIP recommendations should be consulted for information on prevention of JE and settings in which JE vaccine is recommended, can be considered, or is not recommended. Data on the response to a booster dose administered greater than 2 years after the primary series of JE-VC are not available. Data on the need for and timing of additional booster doses also are not available.  This includes long-term travelers ≥1 month, recurrent travelers, or expatriates who will be based in urban areas but are likely to visit endemic rural or agricultural areas during a high-risk period of JE virus transmission.JE vaccine should be considered for short-term (less than 1 month) travelers whose itinerary or activities might increase their risk for exposure to JE virus. JE vaccine is not recommended for short-term travelers whose visit will be restricted to urban areas. The series should be completed ≥1 week before travel.\tJapanese Encephalitis\t42597\tNo Doses Administered\t42605\t43589\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0090\tPatient is an adult traveling to an endemic area with Japanese Encephalitis for longer than a month, and has received the first dose of the Japanese Encephalitis risk 2 dose series vaccine.\t30864\tF\t165\tLonger-term (e.g., 1 month or more) travel to a JE-endemic area\t\t\t\t\t\t\t\tNot Complete\t42597\tJapanese Encephalitis, VC\t134\tVAL\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t42604\t42604\t42624\tACIP recommends that if the primary series of JE-VC was administered greater than 1 year previously, a booster dose may be given before potential JE virus exposure. ACIP recommendations should be consulted for information on prevention of JE and settings in which JE vaccine is recommended, can be considered, or is not recommended. Data on the response to a booster dose administered greater than 2 years after the primary series of JE-VC are not available. Data on the need for and timing of additional booster doses also are not available.  This includes long-term travelers ≥1 month, recurrent travelers, or expatriates who will be based in urban areas but are likely to visit endemic rural or agricultural areas during a high-risk period of JE virus transmission.JE vaccine should be considered for short-term (less than 1 month) travelers whose itinerary or activities might increase their risk for exposure to JE virus. JE vaccine is not recommended for short-term travelers whose visit will be restricted to urban areas. The series should be completed ≥1 week before travel.\tJapanese Encephalitis\t42597\tAll Valid: Forecast Test\t42605\t43801\tRecommended based on Condition\tUpdated earliest and recommended dates to 7 days. Added description\t4.1\n2016-UC-0091\tPatient is an adult traveling to an endemic area with Japanese Encephalitis for longer than a month, and has received the second dose of the Japanese Encephalitis risk 2 dose series vaccine.\t30569\tM\t165\tLonger-term (e.g., 1 month or more) travel to a JE-endemic area\t\t\t\t\t\t\t\tNot Complete\t42488\tJapanese Encephalitis, VC\t134\tVAL\tValid\trisk\t\t42515\tJapanese Encephalitis, VC\t134\tVAL\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t42880\t42880\t\tACIP recommends that if the primary series of JE-VC was administered greater than 1 year previously, a booster dose may be given before potential JE virus exposure. ACIP recommendations should be consulted for information on prevention of JE and settings in which JE vaccine is recommended, can be considered, or is not recommended. Data on the response to a booster dose administered greater than 2 years after the primary series of JE-VC are not available. Data on the need for and timing of additional booster doses also are not available.  This includes long-term travelers ≥1 month, recurrent travelers, or expatriates who will be based in urban areas but are likely to visit endemic rural or agricultural areas during a high-risk period of JE virus transmission.JE vaccine should be considered for short-term (less than 1 month) travelers whose itinerary or activities might increase their risk for exposure to JE virus. JE vaccine is not recommended for short-term travelers whose visit will be restricted to urban areas. The series should be completed ≥1 week before travel.\tJapanese Encephalitis\t43656\tAll Valid: Forecast Test\t42605\t43665\tRecommended based on Condition\tAdded description, updated based on new MMWR July 2019 recommendations for booster dose.\t4.0\n2016-UC-0092\tPatient is 6 months of age and plans to travel with parent from the U.S. for international travel and has not received the Measles (MMR) vaccine.\t42428\tF\t048\tTravelling Internationally\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t42610\t42610\t42793\t\tMMR\t42610\tNo Doses Administered\t42610\t43580\tRecommended based on Condition\t added description.\t4.0\n2016-UC-0093\tPatient is 6 months of age and is still traveling with parents from the U.S. for international travel and has received the Measles (MMR) risk 1-dose vaccine series.\t42428\tF\t048\tTravelling Internationally\t\t\t\t\t\t\t\tNot Complete\t42610\tMMR\t03\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t42794\t42794\t42941\tChildren who received MMR vaccine before age 12 months should be considered potentially susceptible to all three diseases and should be revaccinated with 2 doses of MMR vaccine, the first dose administered when the child is aged 12 through 15 months (12 months if the child remains in an area where disease risk is high) and the second dose at least 28 days later.\tMMR\t42610\tAll Valid: Forecast Test\t42600\t43580\tRecommended based on Condition\t added description\t4.0\n2016-UC-0094\tPatient is an adult with perinatal HIV infection  who does not have  evidence of severe immunosuppression and who was vaccinated with MMR before establishment of antiviral therapy\t35197\tF\t026\tPersons with perinatal HIV infection who do not have evidence of severe immunosuppression and who were vaccinated with MMR before establishment of antiviral therapy [ART]\t\t120\tBegin Date of antiviral therapy [ART]\t42533\t\t\t\tNot Complete\t35562\tMMR\t03\tMSD\tValid\tstandard\t\t36658\tMMR\t03\tMSD\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t42716\t42716\t\t\tMMR\t42533\tAll Valid: Forecast Test\t42600\t43552\tRecommended based on Condition\tadded description\t4.0\n2016-UC-0095\tPatient is an adult with perinatal HIV infection  who does not have  evidence of severe immunosuppression and who was vaccinated with MMR before establishment of antiviral therapy  who has received his first dose of  the second round of MMR vaccines.\t35197\tF\t026\tPersons with perinatal HIV infection who do not have evidence of severe immunosuppression and who were vaccinated with MMR before establishment of antiviral therapy [ART]\t\t120\tBegin Date of antiviral therapy [ART]\t42533\t\t\t\tNot Complete\t35562\tMMR\t03\tMSD\tValid\tstandard\t\t36658\tMMR\t03\tMSD\tValid\tstandard\t\t42716\tMMR\t03\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t4\t42561\t42561\t\t\tMMR\t42716\tAll Valid: Forecast Test\t42600\t43768\tRecommended based on Condition\tUpdated title and description of test case.\t4.1\n2016-UC-0096\tPatient is an adult with perinatal HIV infection  who does not have  evidence of severe immunosuppression and who was vaccinated with MMR before establishment of antiviral therapy and has received the second dose of the second round of  MMR vaccine.\t35197\tF\t026\tPersons with perinatal HIV infection who do not have evidence of severe immunosuppression and who were vaccinated with MMR before establishment of antiviral therapy [ART]\t\t120\tBegin Date of antiviral therapy [ART]\t42533\t\t\t\tComplete\t35562\tMMR\t03\tMSD\tValid\tstandard\t\t36658\tMMR\t03\tMSD\tValid\tstandard\t\t42716\tMMR\t03\tMSD\tValid\trisk\t\t42747\tMMR\t03\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tMMR\t42747\tAll Valid: Forecast Test\t42600\t43768\tRecommended based on Condition\tUpdated title and description of test case.\t4.1\n2016-UC-0097\tPatient is 18 years of age and is seeking protection against strains of Men B disease.\t35980\tM\t001\tPatient seeks protection\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t39633\t39633\t\t\tMenB\t42555\tNo Doses Administered\t42555\t43580\tRecommended based on Condition\t added description\t4.0\n2016-UC-0098\tPatient is 18 years of age and is seeking protection against strains of Men B disease and has received the first dose  of the Men B  series.\t35980\tM\t001\tPatient seeks protection\t\t\t\t\t\t\t\tNot Complete\t42555\tmeningococcal B, OMV\t163\tPFR\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t42583\t42583\t\t\tMenB\t42555\tAll Valid: Forecast Test\t42600\t43531\tRecommended based on Condition\t added description \t4.0\n2016-UC-0099\tPatient is 18 years of age and seeking protection against strains of Men B disease and has received the second dose of the Men B  dose vaccine series.\t35980\tM\t001\tPatient seeks protection\t\t\t\t\t\t\t\tComplete\t42555\tmeningococcal B, OMV\t163\tPFR\tValid\trisk\t\t42739\tmeningococcal B, OMV\t163\tPFR\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tMenB\t42739\tAll Valid: Forecast Test\t42739\t43531\tRecommended based on Condition\tadded description \t4.0\n2016-UC-0100\tPatient is 10 years of age, has anatomical or functional asplenia and has not received the Meningococcal B vaccine.\t38804\tM\t160\tAnatomical or functional asplenia\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t42457\t42457\t\t\tMenB\t42457\tNo Doses Administered\t42612\t43475\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0101\tPatient is 10 years of age, has anatomical or functional asplenia, and has received the first dose of the Men B risk 2-dose vaccine. \t38804\tM\t160\tAnatomical or functional asplenia\t\t\t\t\t\t\t\tNot Complete\t42457\tmeningococcal B, OMV\t163\tNOV\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t42485\t42485\t\t\tMenB\t42457\tAll Valid: Forecast Test\t42612\t43475\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0102\tPatient is 10 years of age, has anatomical or functional asplenia, and has received the second dose  of the Men B risk 2-dose vaccine. \t38804\tM\t160\tAnatomical or functional asplenia\t\t\t\t\t\t\t\tNot Complete\t42457\tmeningococcal B, OMV\t163\tNOV\tValid\trisk\t\t42641\tmeningococcal B, OMV\t163\tNOV\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t43006\t43006\t\t\tMenB\t42641\tAll Valid: Forecast Test\t42612\t43879\tRecommended based on Condition\t4.2: Updated to add new booster dose per the new Men B recommendations found in the Immunization Schedule 2020\t4.2\n2016-UC-0103\tPatient is a microbiologist routinely exposed to Neisseria Meningitidis.\t28034\tF\t050\tMicrobiologists routinely exposed to Neisseria meningitidis\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t31686\t31686\t\t\tMenB\t42544\tNo Doses Administered\t42620\t43475\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0104\tPatient is a microbiologist routinely exposed to Neisseria Meningitidis and has received the first dose of the Men B vaccine\t28034\tF\t050\tMicrobiologists routinely exposed to Neisseria meningitidis\t\t\t\t\t\t\t\tNot Complete\t42544\tmeningococcal B, recombinant \t162\tPFR\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t42572\t42572\t42599\t\tMenB\t42544\tAll Valid: Forecast Test\t42620\t43801\tRecommended based on Condition\tAdded past due date.  Updated based on change in version 3.4. Dose 2 can be administered at 4 weeks - 4 days, 4 weeks, added description.\t4.1\n2016-UC-0105\tMicrobiologist routinely exposed to Neisseria Meningitidis and has received the second dose  of the Men B risk 3 dose series\t28034\tF\t050\tMicrobiologists routinely exposed to Neisseria meningitidis\t\t\t\t\t\t\t\tNot Complete\t42544\tmeningococcal B, recombinant \t162\tPFR\tValid\trisk\t\t42572\tmeningococcal B, recombinant\t162\tPFR\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t42727\t42727\t\t\tMenB\t42572\tAll Valid: Forecast Test\t42620\t43801\tRecommended based on Condition\tUpdated Earliest and Recommended dates, added description \t4.1\n2016-UC-0106\tMicrobiologist routinely exposed to Neisseria Meningitidis and has received three doses of the Men B risk 3 dose series\t28034\tF\t050\tMicrobiologists routinely exposed to Neisseria meningitidis\t\t\t\t\t\t\t\tNot Complete\t42544\tmeningococcal B, recombinant \t162\tPFR\tValid\trisk\t\t42572\tmeningococcal B, recombinant\t162\tPFR\tValid\trisk\t\t42756\tmeningococcal B, recombinant\t162\tPFR\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t4\t43121\t43121\t\t\tMenB\t42756\tAll Valid: Forecast Test\t42620\t43868\tRecommended based on Condition\t4.2: Updated to forecast booster dose\t4.2\n2016-UC-0107\t8 week old infant with anatomical or functional asplenia and has not received Meningococcal vaccine.\t42049\tM\t160\tAnatomical or functional asplenia\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t42108\t42108\t\tIf MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses.\tMeningococcal\t42108\tNo Doses Administered\t42620\t43475\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0108\tPatient is an infant with anatomical or functional asplenia and has received the first dose of the Meningococcal ACWY vaccine.\t42049\tM\t160\tAnatomical or functional asplenia\t\t\t\t\t\t\t\tNot Complete\t42108\tMeningococcal, MCV4O \t136\tNOV\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t42164\t42169\t\tIf MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses.\tMeningococcal\t42108\tAll Valid: Forecast Test\t42620\t44358\tRecommended based on Condition\tUpdated the Recommended Date\t4.2\n2016-UC-0109\tPatient is an infant with anatomical or functional asplenia and has received the second dose of the Meningococcal ACWY vaccine.\t42049\tM\t160\tAnatomical or functional asplenia\t\t\t\t\t\t\t\tNot Complete\t42108\tMeningococcal, MCV4O \t136\tNOV\tValid\trisk\t\t42164\tMeningococcal, MCV4O \t136\tNOV\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t42220\t42230\t\tIf MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses.\tMeningococcal\t42164\tAll Valid: Forecast Test\t42620\t44358\tRecommended based on Condition\tUpdated the Recommended Date\t4.2\n2016-UC-0110 \tPatient is an  infant with anatomical or functional asplenia and has receive the third  dose of the Meningococcal ACWY vaccine.\t42049\tM\t160\tAnatomical or functional asplenia\t\t\t\t\t\t\t\tNot Complete\t42108\tMeningococcal, MCV4O \t136\tNOV\tValid\trisk\t\t42164\tMeningococcal, MCV4O \t136\tNOV\tValid\trisk\t\t42220\tMeningococcal, MCV4O \t136\tNOV\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t4\t42404\t42414\t\tIf MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses.\tMeningococcal\t42220\tAll Valid: Forecast Test\t42621\t44358\tRecommended based on Condition\tUpdated the Recommended Date\t4.2\n2016-UC-0111\tPatient is an 12 month old infant with anatomical or  functional asplenia and has  received all four doses of the Meningococcal ACWY vaccine.\t42049\tM\t160\tAnatomical or functional asplenia\t\t\t\t\t\t\t\tNot Complete\t42108\tMeningococcal, MCV4O \t136\tNOV\tValid\trisk\t\t42164\tMeningococcal, MCV4O \t136\tNOV\tValid\trisk\t\t42220\tMeningococcal, MCV4O \t136\tNOV\tValid\trisk\t\t42414\tMeningococcal, MCV4O \t136\tNOV\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t5\t43510\t43510\t\tIf MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses.\tMeningococcal\t42414\tAll Valid: Forecast Test\t42621\t43479\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0112\tPatient is a 4 year old child who has anatomical or functional asplenia, has completed the primary doses, and has received the first booster dose at 3 years later.\t41144\tM\t160\tAnatomical or functional asplenia\t\t\t\t\t\t\t\tNot Complete\t41205\tMeningococcal, MCV4O \t136\tNOV\tValid\trisk\t\t41261\tMeningococcal, MCV4O \t136\tNOV\tValid\trisk\t\t41317\tMeningococcal, MCV4O \t136\tNOV\tValid\trisk\t\t41509\tMeningococcal, MCV4O \t136\tNOV\tValid\trisk\t\t42605\tMeningococcal, MCV4O \t136\tNOV\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t6\t44431\t44431\t\tIf MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses.\tMeningococcal\t42605\tAll Valid: Forecast Test\t42621\t43479\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0113\tPatient is a 9 year old child who has anatomical or functional asplenia and has received the 3 year booster dose as well as the 5 year booster dose of the Meningococcal ACWY risk start before 7 months series.\t39083\tM\t160\tAnatomical or functional asplenia\t\t\t\t\t\t\t\tNot Complete\t39142\tMeningococcal, MCV4O \t136\tNOV\tValid\trisk\t\t39198\tMeningococcal, MCV4O \t136\tNOV\tValid\trisk\t\t39254\tMeningococcal, MCV4O \t136\tNOV\tValid\trisk\t\t39448\tMeningococcal, MCV4O \t136\tNOV\tValid\trisk\t\t40544\tMeningococcal, MCV4O \t136\tNOV\tValid\trisk\t\t42370\tMeningococcal, MCV4O \t136\tNOV\tValid\trisk\t\t\t\t\t\t\t\t\t7\t44197\t44197\t\tIf MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses.\tMeningococcal\t42370\tAll Valid: Forecast Test\t42621\t43479\tRecommended based on Condition\tAdded Description\t4.0\n2016-UC-0114\t7 month old infant (with no previous history of Meningococcal vaccine)  at risk for Meningococcal disease during a community outbreak. \t42134\tF\t070\tPersons at risk during an outbreak\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t42195\t42195\t\tIf MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses.\tMeningococcal\t42348\tNo Doses Administered\t42621\t44358\tRecommended based on Condition\tUpdated the Earliest and Recommended dates\t4.2\n2016-UC-0115\tPatient is a 7 month old infant and is at risk during a community outbreak of Meningococcal disease and has received the first dose of the Meningococcal ACWY vaccine.\t42134\tF\t070\tPersons at risk during an outbreak\t\t\t\t\t\t\t\tNot Complete\t42348\tMeningococcal, MCV4O \t136\tNOV\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t42500\t42500\t\tIf MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses.\tMeningococcal\t42348\tAll Valid: Forecast Test\t42622\t44358\tRecommended based on Condition\tUpdated the Earliest and Recommended dates\t4.2\n2016-UC-0116\tPatient is a 12 months old and was at risk during a community outbreak of Meningococcal disease and has received the second dose of the Meningococcal ACWY risk start after 7 months 2 dose vaccine.\t42134\tF\t070\tPersons at risk during an outbreak\t\t\t\t\t\t\t\tNot Complete\t42348\tMeningococcal, MCV4O \t136\tNOV\tValid\trisk\t\t42500\tMeningococcal, MCV4O \t136\t\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t43595\t43595\t\tIf MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses.\tMeningococcal\t42500\tAll Valid: Forecast Test\t42622\t43475\tRecommended based on Condition\tadded description\t4.0\n2016-UC-0117\t2 month old infant, with persistent complement deficiencies, and has not received any doses of the Meningococcal vaccine.\t42213\tM\t151\tPersistent complement, properdin, or factor B deficiency\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t42275\t42275\t\tIf MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses.\tMeningococcal\t42277\tNo Doses Administered\t42622\t43801\tRecommended based on Condition\tUpdated Assessment Date. Added description\t4.1\n2016-UC-0123\tAdult with no known history of meningococcal vaccination and has  anatomical or functional asplenia\t33712\tM\t160\tAnatomical or functional asplenia\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t34442\t34442\t\tIf MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses.\tMeningococcal\t42492\tAll Valid: Forecast Test\t42622\t43480\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0124\tPatient is and adult with anatomical or functional asplenia and has received the first dose of the Meningococcal ACWY risk 2 dose series vaccine\t33712\tM\t160\tAnatomical or functional asplenia\t\t\t\t\t\t\t\tNot Complete\t42492\tMeningococcal, MCV4O \t136\tNOV\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t42548\t42548\t42575\tIf MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses.\tMeningococcal\t42492\tAll Valid: Forecast Test\t42622\t43531\tRecommended based on Condition\t added description\t4.0\n2016-UC-0125\tPatient is an adult with anatomical or functional asplenia and has received the second dose of the Meningococcal ACWY risk 2 dose series vaccines.\t33712\tM\t160\tAnatomical or functional asplenia\t\t\t\t\t\t\t\tNot Complete\t42492\tMeningococcal, MCV4O \t136\tNOV\tValid\trisk\t\t42548\tMeningococcal, MCV4O \t136\tNOV\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t44374\t44374\t\tIf MenACWY-D is used, it should be administered at least 4 weeks after completion of all PCV doses.\tMeningococcal\t42548\tAll Valid: Forecast Test\t42622\t43531\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0127\tPatient is a first year college student living in a residence hall and has received the Meningococcal ACWY risk 1 dose series.\t35447\tF\t046\tCollege students living in residence halls\t\t\t\t\t\t\t\tComplete\t42386\tMeningococcal, MCV4P\t114\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tMeningococcal\t42386\tAll Valid: Forecast Test\t42612\t43531\tRecommended based on Condition\tadded description\t4.0\n2016-UC-0128\tPatient is 60 years of age (vaccine naïve) and at risk during a Meningococcal outbreak.\t20521\tM\t070\tPersons at risk during an outbreak\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t21251\t21251\t\tMeningococcal vaccines that are licensed for use in person aged ≥56 year are not currently available in the United States  Persons aged ≥56 years who are recommended meningococcal vaccination because they are at increased risk for meningococcal disease should receive MenACWY conjugate vaccine\tMeningococcal\t42612\tNo Doses Administered\t42612\t43546\tRecommended based on Condition\t, added description\t4.0\n2016-UC-0129\tPatient is 60 years of age, at risk during a Meningococcal outbreak, and has received the Meningococcal risk 1 dose vaccine.\t20521\tM\t070\tPersons at risk during an outbreak\t\t\t\t\t\t\t\tNot Complete\t42513\tMeningococcal, MPSV4 \t32\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t44339\t44339\t\tMeningococcal vaccines that are licensed for use in person aged ≥56 year are not currently available in the United States  Persons aged ≥56 years who are recommended meningococcal vaccination because they are at increased risk for meningococcal disease should receive MenACWY conjugate vaccine\tMeningococcal\t42513\tAll Valid: Forecast Test\t42612\t43546\tRecommended based on Condition\t added description.\t4.0\n2016-UC-0130\tPatient is pregnant, and at 27 weeks of gestation, and has not received the Pertussis vaccine (Tdap)\t32317\tF\t007\tPregnant\t\t170\tOnset of pregnancy\t42604\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t\t42427\t42856\tAdminister during each pregnancy (preferably during 27 to 36 weeks’ gestation) regardless of interval since prior Td or Tdap vaccination.\tDTaP\t42604\tNo Doses Administered\t42605\t43552\tRecommended based on Condition\tadded description\t4.0\n2016-UC-0131\tPatient is pregnant, at 27 weeks of gestation, and has received a Tdap\t32317\tF\t007\tPregnant\t\t170\tOnset of pregnancy\t42604\t\t\t\tComplete\t42795\tTdap\t115\tSKB\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\tAdminister during each pregnancy (preferably during 27 to 36 weeks’ gestation) regardless of interval since prior Td or Tdap vaccination.\tDTaP\t42795\tAll Valid: Forecast Test\t42605\t43552\tRecommended based on Condition\tadded description\t4.0\n2016-UC-0132\tLaboratory worker who handles specimens that might contain Polio and has completed a Polio standard series, but has not received any additional doses.\t28452\tM\t054\tLaboratory workers who handle specimens that might contain polioviruses\t\t\t\t\t\t\t\tNot Complete\t28513\tIPV\t10\tPMC\tValid\tstandard\t\t28541\tIPV\t10\tPMC\tValid\tstandard\t\t28817\tIPV\t10\tPMC\tValid\tstandard\t\t29984\tIPV\t10\tPMC\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t5\t35026\t35026\t35026\t\tIPOL\t42464\tAll Valid: Forecast Test\t42601\t43480\tRecommended based on Condition\tAdded description and Updated past due date  \t4.0\n2016-UC-0133\tPatient is a laboratory worker who handles specimens that might contain Polio and has completed a Polio standard dose series and the additional risk dose.\t28452\tM\t054\tLaboratory workers who handle specimens that might contain polioviruses\t\t\t\t\t\t\t\tComplete\t28513\tIPV\t10\tPMC\tValid\tstandard\t\t28541\tIPV\t10\tPMC\tValid\tstandard\t\t28817\tIPV\t10\tPMC\tValid\tstandard\t\t29984\tIPV\t10\tPMC\tValid\tstandard\t\t42464\tIPV\t10\tPMC\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tIPOL\t42464\tAll Valid: Forecast Test\t42601\t43480\tRecommended based on Condition\tUpdated test case description and first dose administration to match more closely to the recommendations for adults at risk for polio and added description\t4.0\n2016-UC-0134\tPatient is 55 years of age, with no previous history of the polio vaccine, and plans on traveling to areas or countries where polio is endemic.\t22503\tF\t143\tTravel to areas or countries where polio is epidemic or endemic\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t29077\t29077\t\t\tIPOL\t42618\tNo Doses Administered\t42618\t43480\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0135\tPatient is traveling to areas or countries where polio is endemic and has received the first dose of the polio risk adult vaccine.\t22503\tF\t143\tTravel to areas or countries where polio is epidemic or endemic\t\t\t\t\t\t\t\tNot Complete\t42618\tIPV\t10\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t42646\t42646\t42673\t\tIPOL\t42618\tAll Valid: Forecast Test\t42601\t43480\tRecommended based on Condition\tAdded Past Due date, added description\t4.0\n2016-UC-0136\tPatient is traveling to areas or countries where polio is endemic and has received the second dose of the polio risk adult vaccine.\t22503\tF\t143\tTravel to areas or countries where polio is epidemic or endemic\t\t\t\t\t\t\t\tNot Complete\t42618\tIPV\t10\tPMC\tValid\trisk\t\t42646\tIPV\t10\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t42828\t42828\t43010\t\tIPOL\t42646\tAll Valid: Forecast Test\t42601\t43480\tRecommended based on Condition\tAdded Past Due date, added description\t4.0\n2016-UC-0137\tPatient is traveling to areas or countries where polio is an epidemic and has received all three doses of the polio risk adult vaccine.\t22503\tF\t143\tTravel to areas or countries where polio is epidemic or endemic\t\t\t\t\t\t\t\tComplete\t42618\tIPV\t10\tPMC\tValid\trisk\t\t42646\tIPV\t10\tPMC\tValid\trisk\t\t42828\tIPV\t10\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tIPOL\t42828\tAll Valid: Forecast Test\t42601\t43480\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0138\tPatient is a Rabies Researcher with a history (before 05/06/2022) of three doses of the Rabies vaccine.\t29998\tF\t053\tRabies researchers\t\t\t\t\t\t\t\tNot Complete\t42183\tRabies, intramuscular injection\t175\tNOV\tValid\trisk\t\t42190\tRabies, intramuscular injection\t175\tNOV\tValid\trisk\t\t42204\tRabies, intramuscular injection\t175\tNOV\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t4\t42388\t42388\t\tThe 6 month booster should only be given after a rabies antibody titer. The booster should be administered if the titer falls below 0.5 IU/mL.\tRabies\t42204\tAll Valid: Forecast Test\t42608\t44718\tRecommended based on interval\tUpdated the test case name and general description 4.0 Added description\t4.4\n2016-UC-0139\tPatient is a Rabies Researcher and has been administered a booster dose (after being tested and found to have a fallen serum titer)  of the Rabies risk continuous exposure series.  \t29998\tF\t053\tRabies researchers\t\t\t\t\t\t\t\tNot Complete\t42183\tRabies, intramuscular injection\t175\tNOV\tValid\trisk\t\t42190\tRabies, intramuscular injection\t175\tNOV\tValid\trisk\t\t42204\tRabies, intramuscular injection\t175\tNOV\tValid\trisk\t\t42388\tRabies, intramuscular injection\t175\tNOV\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t5\t42570\t42570\t\tThe 6 month booster should only be given after a rabies antibody titer. The booster should be administered if the titer falls below 0.5 IU/mL.\tRabies\t42388\tAll Valid: Forecast Test\t42608\t44718\tRecommended based on interval\tUpdated the test case name and general description 4.0 Updated forecast date to reflect dose #5 at 6 months, added description.\t4.4\n2016-UC-0140\tNew Rabies Researcher with no previous history of the Rabies vaccine. \t31676\tM\t053\tRabies researchers\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t31676\t31676\t\tThe 6 month booster should only be given after a rabies antibody titer. The booster should be administered if the titer falls below 0.5 IU/mL.\tRabies\t42506\tNo Doses Administered\t42608\t43481\tRecommended based on Condition\tUpdated forecast dates to reflect an indication begin age of 0 instead of 18 for the risk, added description.  \t4.0\n2016-UC-0141\tPatient is a new Rabies Researcher and has been administered the first dose (after 05/06/2022) of the Rabies risk continuous expsosure vaccine series.\t31676\tM\t053\tRabies researchers\t\t\t\t\t\t\t\tNot Complete\t44688\tRabies, intramuscular injection\t175\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t44695\t44695\t\t\tRabies\t44688\tAll Valid: Forecast Test\t42608\t44714\tRecommended based on interval\tUpdated the first dose date, forecast earliest, and forecast recommended dates to more closely align with the changes in the Rabies MMWR for 2022 added CVX code 175, added description\t4.4\n2016-UC-0142\tPatient is a new Rabies Researcher and has received the second dose of the Rabies risk continuous exposure vaccine series.\t31676\tM\t053\tRabies researchers\t\t\t\t\t\t\t\tNot Complete\t44688\tRabies, intramuscular injection\t175\tPMC\tValid\trisk\t\t44695\tRabies, intramuscular injection\t175\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t44879\t44879\t\t\tRabies\t44695\tAll Valid: Forecast Test\t42608\t44714\tRecommended based on interval\tUpdated the first and second dose dates, forecast earliest, and forecast recommended dates to more closely align with the changes in the Rabies MMWR for 2022 added CVX code 175, added description\t4.4\n2016-UC-0143\tPatient is a new Rabies Researcher and has been administered three doses (all after 05/06/2022) of the Rabies risk continuous exposure vaccine series.\t31676\tM\t053\tRabies researchers\t\t\t\t\t\t\t\tNot Complete\t44688\tRabies, intramuscular injection\t175\tPMC\tValid\trisk\t\t44695\tRabies, intramuscular injection\t175\tPMC\tValid\trisk\t\t44879\tRabies, intramuscular injection\t175\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t4\t45060\t45060\t\tThe 6 month booster should only be given after a rabies antibody titer.  The boostere should be administered if the titier falls below 0.5 IU/mL. \tRabies\t44879\tAll Valid: Forecast Test\t42611\t44714\tRecommended based on interval\tUpdated the first, second, and third dose dates, forecast earliest and forecast recommended dates to more closely align with the changes in the Rabies MMWR for 2022 Updated test case to forecast a fourth dose at 6 months, added description.\t4.4\n2016-UC-0144\tPatient is a person who frequently performs animal necropsies and has a previous history (all before 05/06/2022) of the Rabies vaccine but has been tested and found to have a fallen serum titer. \t32885\tF\t222\tPersons who frequently perform animal necropsies\t\t\t\t\t\t\t\tNot Complete\t44000\tRabies, intramuscular injection\t175\tPMC\tValid\trisk\t\t44007\tRabies, intramuscular injection\t175\tPMC\tValid\trisk\t\t44021\tRabies, intramuscular injection\t175\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t4\t44751\t44751\t\tThe 2 year booster should only be given after a rabies antibody titer. The booster should be administered if the titer falls below 0.5 IU/mL.\tRabies\t44021\tAll Valid: Forecast Test\t42611\t44715\tRecommended based on Condition\tUpdated test case names and first, second, and third dose dates, updated earliest and recommended dates to more closely aligned with the current Rabies MMWR 2022.  added description\t4.4\n2016-UC-0145\tPatient is a person who frequently performs animal necropsies and has received a booster dose of the Rabies risk frequent series.\t32885\tF\t222\tPersons who frequently perform animal necropsies\t\t\t\t\t\t\t\tNot Complete\t44000\tRabies, intramuscular injection\t175\tPMC\tValid\trisk\t\t44007\tRabies, intramuscular injection\t175\tPMC\tValid\trisk\t\t44021\tRabies, intramuscular injection\t175\tPMC\tValid\trisk\t\t44751\tRabies, intramuscular injection\t175\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t5\t45482\t45482\t\tThe 2 year booster should only be given after a rabies antibody titer. The booster should be administered if the titer falls below 0.5 IU/mL.\tRabies\t44751\tAll Valid: Forecast Test\t42611\t44715\tRecommended based on interval\tUpdated test case names and first, second, third and fourth dose dates, updated earliest and recommended dates to more closely aligned with the current Rabies MMWR 2022.  added description\t4.4\n2016-UC-0146\tPatient is 46 years of age and travelling to an area at risk of exposure to  S. Typhi.\t25677\tM\t163\tTravel to areas in which there is a recognized risk of exposure to S. typhi\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t26408\t26408\t\t\tTyphoid\t42573\tNo Doses Administered\t42601\t43531\tRecommended based on Condition\t added description.\t4.0\n2016-UC-0147\tPatient is traveling to an area at risk of exposure to  S. Typhi and has received the Typhoid risk 1 dose vaccine series two weeks before potential exposure.\t25677\tM\t163\tTravel to areas in which there is a recognized risk of exposure to S. typhi\t\t\t\t\t\t\t\tNot Complete\t42573\tTyphoid capsular polysaccharide\t101\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t43303\t43303\t\tThis vaccine should be given at least 2 weeks before potential exposure.  Primary vaccination with live-attenuated Ty21a vaccine consists of one enteric-coated capsule taken on alternate days (day 0, 2, 4, and 6), for a total of four capsules. The capsules must be kept refrigerated (not frozen). Each capsule should be taken with cool water no warmer than 98.6°F (37.0°C), approximately 1 hour before a meal. All doses should be completed at least 1 week before potential exposure.\tTyphoid\t42573\tAll Valid: Forecast Test\t42601\t43481\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0148\tTwo years later, patient continues  to travel to an area at risk of exposure to  S. Typhi and has received the booster dose of the Typhoid risk 1-dose series.\t25677\tM\t163\tTravel to areas in which there is a recognized risk of exposure to S. typhi\t\t\t\t\t\t\t\tNot Complete\t42573\tTyphoid capsular polysaccharide\t101\tPMC\tValid\trisk\t\t43303\tTyphoid capsular polysaccharide\t101\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t44034\t44034\t\tThis vaccine should be given at least 2 weeks before potential exposure.  Primary vaccination with live-attenuated Ty21a vaccine consists of one enteric-coated capsule taken on alternate days (day 0, 2, 4, and 6), for a total of four capsules. The capsules must be kept refrigerated (not frozen). Each capsule should be taken with cool water no warmer than 98.6°F (37.0°C), approximately 1 hour before a meal. All doses should be completed at least 1 week before potential exposure.\tTyphoid\t43303\tAll Valid: Forecast Test\t42601\t43481\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0149\tMicrobiology laboratorian who works frequently with S. typhi carrier and has not received the Typhoid vaccine.\t29509\tM\t051\tMicrobiology laboratorians who work frequently with S. typhi\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t30239\t30239\t\tThis vaccine should be given at least 2 weeks before potential exposure.  Primary vaccination with live-attenuated Ty21a vaccine consists of one enteric-coated capsule taken on alternate days (day 0, 2, 4, and 6), for a total of four capsules. The capsules must be kept refrigerated (not frozen). Each capsule should be taken with cool water no warmer than 98.6°F (37.0°C), approximately 1 hour before a meal. All doses should be completed at least 1 week before potential exposure.\tTyphoid\t42598\tNo Doses Administered\t42611\t43587\tRecommended based on Condition\tUpdated test case to forecast dose number 1 at age 6 years of age, added description.\t4.0\n2016-UC-0150\tPatient is a microbiology laboratorian who works frequently with S. typhi carrier and has received the Typhoid vaccine.\t29509\tM\t051\tMicrobiology laboratorians who work frequently with S. typhi\t\t\t\t\t\t\t\tNot Complete\t42598\tTyphoid oral, live, attenuated\t25\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t44424\t44424\t\tThis vaccine should be given at least 2 weeks before potential exposure.  Primary vaccination with live-attenuated Ty21a vaccine consists of one enteric-coated capsule taken on alternate days (day 0, 2, 4, and 6), for a total of four capsules. The capsules must be kept refrigerated (not frozen). Each capsule should be taken with cool water no warmer than 98.6°F (37.0°C), approximately 1 hour before a meal. All doses should be completed at least 1 week before potential exposure.\tTyphoid\t42598\tAll Valid: Forecast Test\t42611\t43481\tRecommended based on Condition\tUpdated the CVX code to 25, added description\t4.0\n2016-UC-0151\tPatient is 52 years of age and travelling to a country at risk for Yellow Fever transmission. \t23559\tF\t162\tTravel to areas at risk for Yellow Fever transmission\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t23833\t23833\t\tA single primary dose of yellow fever vaccine provides long-lasting protection and is adequate for most travelers but additional doses of yellow fever vaccine are recommended for certain travelers with ongoing risk.  Women who were pregnant (regardless of trimester) when they received their initial dose of yellow fever vaccine should receive 1 additional dose of yellow fever vaccine  Persons who received a hematopoietic stem cell transplant after receiving a dose of yellow fever vaccine and who are sufficiently immunocompetent to be safely vaccinated should be revaccinated.  A booster dose may be given to travelers who received their last dose of yellow fever vaccine at least 10 years previously and who will be in a higher-risk setting based on season, location, activities, and duration of their travel.  Persons who were infected with HIV when they received their last dose of yellow fever vaccine should receive a dose every 10 years if they continue to be at risk for yellow fever virus infection.\tYellow Fever\t42614\tNo Doses Administered\t42604\t43481\tRecommended based on Condition\tadded description\t4.0\n2016-UC-0152\tPatient is travelling to a country at risk for Yellow Fever transmission and has received the Yellow Fever risk 1 dose series.\t23559\tF\t162\tTravel to areas at risk for Yellow Fever transmission\t\t\t\t\t\t\t\tComplete\t42614\tYellow Fever\t37\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\tA single primary dose of yellow fever vaccine provides long-lasting protection and is adequate for most travelers but additional doses of yellow fever vaccine are recommended for certain travelers with ongoing risk.  Women who were pregnant (regardless of trimester) when they received their initial dose of yellow fever vaccine should receive 1 additional dose of yellow fever vaccine  Persons who received a hematopoietic stem cell transplant after receiving a dose of yellow fever vaccine and who are sufficiently immunocompetent to be safely vaccinated should be revaccinated.  A booster dose may be given to travelers who received their last dose of yellow fever vaccine at least 10 years previously and who will be in a higher-risk setting based on season, location, activities, and duration of their travel.  Persons who were infected with HIV when they received their last dose of yellow fever vaccine should receive a dose every 10 years if they continue to be at risk for yellow fever virus infection.\tYellow Fever\t42614\tAll Valid: Forecast Test\t42604\t43481\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0153\tChild is 3 years old with cochlear implants,  and has an incomplete schedule (only received 1 dose at 4 months) of the PCV 13 series.\t41282\tM\t011\tCochlear implants\t\t\t\t\t\t\t\tNot Complete\t41402\tPCV 13\t133\tPFR\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t41458\t41458\t\tWhen cochlear implant placement is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy.\tPneumococcal\t42412\tAll Valid: Forecast Test\t42612\t43482\tRecommended based on Condition\tUpdated to reflect the correct forecasting date, added description.\t4.0\n2016-UC-0154\tPatient is 3 years old with cochlear implants, has received one standard dose of the PCV 13 series and has received the first dose of the risk 2-5 years 3 dose series.\t41282\tM\t011\tCochlear implants\t\t\t\t\t\t\t\tNot Complete\t41402\tPCV 13\t133\tPFR\tValid\tstandard\t\t42412\tPCV 13\t133\tPFR\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t42468\t42468\t\tWhen cochlear implant placement is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy.\tPneumococcal\t42412\tAll Valid: Forecast Test\t42612\t43482\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0155\tPatient is 3 years old with cochlear implants, and has received one standard dose of the  PCV 13 series and has received the second dose of the risk 2-5 years 3 dose series.\t41282\tM\t011\tCochlear implants\t\t\t\t\t\t\t\tNot Complete\t41402\tPCV 13\t133\tPFR\tValid\tstandard\t\t42412\tPCV 13\t133\tPFR\tValid\trisk\t\t42468\tPCV 13\t133\t\tValid\tRisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t4\t42524\t42524\t\tWhen cochlear implant placement is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy.\tPneumococcal\t42468\tAll Valid: Forecast Test\t42612\t43482\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0156\tPatient is 4 years old with cochlear implants, has received three doses of the PCV13 vaccine, and one dose of the PPSV23 vaccine.\t41046\tM\t011\tCochlear implants\t\t\t\t\t\t\t\tNot Complete\t41179\tPCV 13\t133\tPFR\tValid\tstandard\t\t41256\tPCV 13\t133\tPFR\tValid\trisk\t\t41411\tPCV 13\t133\tPFR or WAL\tValid\trisk\t\t42511\tPPSV23\t33\tPFR or WAL\tValid\tRisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t5\t64787\t64787\t\tWhen cochlear implant placement is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy.\tPneumococcal\t42511\tAll Valid: Forecast Test\t42613\t43482\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0157\tPatient is adult that smokes cigarettes and has not received a PCV vaccine.\t35497\tF\t042\tSmoke cigarettes\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t42437\t42437\t\t\tPneumococcal\t44592\tNo Doses Administered\t42612\t44592\tRecommended based on Condition\tUpdated test case minimum and recommended interval to reflect updated indication begin age for individual who is a smoker based on current MMWR publish 01/2022.\t4.4\n2016-UC-0158\tPatient is an adult that smokes cigarettes and has received the PPSV23 vaccine. \t35604\tF\t042\tSmoke cigarettes\t\t\t\t\t\t\t\tNot Complete\t42629\tPPSV23\t33\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t42994\t42994\t\t\tPneumococcal\t44586\tAll Valid: Forecast Test\t42612\t44586\tRecommended based on Condition\tupdated test case per ACIP recommendation for PCV/PC15/20 and MMWR 01/22\t4.4\n2016-UC-0159\tChild is 8 years of age with  cerebrospinal fluid leaks and has not received (vaccine naive)PCV13 nor PPSV23 vaccine.\t39705\tM\t010\tCerebrospinal fluid leaks\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t41896\t41896\t\t\tPneumococcal\t42627\tNo Doses Administered\t42614\t43482\tRecommended based on Condition\tadded description\t4.0\n2016-UC-0160\tPatient is 8 years of age and has cerebrospinal fluid leaks and has received the PCV13 vaccine but not the PPSV23 vaccine.\t39705\tM\t010\tCerebrospinal fluid leaks\t\t\t\t\t\t\t\tNot Complete\t42627\tPCV 13\t133\tPFR\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t42683\t42683\t\t\tPneumococcal\t42627\tAll Valid: Forecast Test\t42614\t43482\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0161\tPatient is 8 years of age, has cerebrospinal fluid leaks and has received a dose of the PCV 13 and a dose of the PPSV23 vaccine. \t39705\tM\t010\tCerebrospinal fluid leaks\t\t\t\t\t\t\t\tNot Complete\t42627\tPCV 13\t133\tPFR\tValid\trisk\t\t42683\tPPSV 23\t33\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t63446\t63446\t\t\tPneumococcal\t42683\tAll Valid: Forecast Test\t42614\t43482\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0162\tPatient is 15 years of age and has cerebrospinal fluid leaks and has received a dose of the PPSV23 vaccine but not the PCV vaccine.\t36966\tF\t010\tCerebrospinal fluid leaks\t\t\t\t\t\t\t\tNot Complete\t42492\tPPSV 23\t33\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t42548\t42548\t\t\tPneumococcal\t42492\tAll Valid: Forecast Test\t42614\t43482\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0163\tPatient is 15 years of age and has cerebrospinal fluid leaks and has received the second dose of the Pneumococcal risk 2-dose PPSV-PCV series vaccine. \t36966\tF\t010\tCerebrospinal fluid leaks\t\t\t\t\t\t\t\tNot Complete\t42492\tPPSV 23\t33\tMSD\tValid\trisk\t\t42548\tPCV 13\t133\tPFR\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t60707\t60707\t\t\tPneumococcal\t42548\tAll Valid: Forecast Test\t42614\t43482\tRecommended based on Condition\tadded description\t4.0\n2016-UC-0164\tPatient is an adult that, has cochlear implants, and has received the PPSV23 vaccine but not  PCV.\t28246\tM\t011\tCochlear implants\t\t\t\t\t\t\t\tNot Complete\t42583\tPPSV 23\t33\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t42948\t42948\t\tWhen cochlear implant placement is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy.\tPneumococcal\t42583\tAll Valid: Forecast Test\t42615\t44593\tRecommended based on interval\tUpdate the title and description to reflect the current recommendations per MMWR 1/2022\t4.4\n2016-UC-0165\tPatient is 39 years of age, has cochlear implants, has received the PCV vaccine one year after the PPSV23 vaccine dose. \t28246\tM\t011\tCochlear implants\t\t\t\t\t\t\t\tNot Complete\t42583\tPPSV 23\t33\tMSD\tValid\trisk\t\t42948\tPCV 13\t133\tPFR\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t51987\t51987\t\tWhen cochlear implant placement is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy.\tPneumococcal\t42948\tAll Valid: Forecast Test\t42615\t43482\tRecommended based on Condition\tUpdated forecast vaccine type, added description\t4.0\n2016-UC-0166\tPatient is a two year old child with sickle cell disease, who has completed the PCV 13 vaccine standard series but has not received a dose of the PPSV 23 vaccine.\t40258\tF\t160\tAnatomical or functional asplenia\t\t\t\t\t\t\t\tNot Complete\t40319\tPCV 13\t133\tPFR\tValid\tstandard\t\t40380\tPCV 13\t133\tPFR\tValid\tstandard\t\t40442\tPCV 13\t133\tPFR\tValid\tstandard\t\t41050\tPCV 13\t133\tPFR\tValid\tstandard\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t5\t41106\t41106\t\tWhen elective splenectomy is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy.\tPneumococcal\t41050\tAll Valid: Forecast Test\t42615\t43593\tRecommended based on Condition\tUpdated age of patient in 4 dose. Added description\t4.0\n2016-UC-0167\tPatient is 6 years of age, has sickle cell disease, has completed the PCV 13 standard vaccine series, and has received a dose of PPSV23 series. \t40258\tF\t160\tAnatomical or functional asplenia\t\t\t\t\t\t\t\tNot Complete\t40319\tPCV 13\t133\tPFR\tValid\tstandard\t\t40380\tPCV 13\t133\tPFR\tValid\tstandard\t\t40442\tPCV 13\t133\tPFR\tValid\tstandard\t\t41050\tPCV 13\t133\tPFR\tValid\tstandard\t\t42518\tPPSV 23\t33\tMSD\tValid\tRisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t6\t44344\t44344\t\tWhen elective splenectomy is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy.\tPneumococcal\t42518\tAll Valid: Forecast Test\t42615\t43482\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0168\tPatient is now 11 years of age, has sickle cell disease, has completed the PCV 13 standard vaccine series, received the first and 5 year booster dose of PPSV23 series.\t40258\tF\t160\tAnatomical or functional asplenia\t\t\t\t\t\t\t\tNot Complete\t40319\tPCV 13\t133\tPFR\tValid\tstandard\t\t40380\tPCV 13\t133\tPFR\tValid\tstandard\t\t40442\tPCV 13\t133\tPFR\tValid\tstandard\t\t40684\tPCV 13\t133\tPFR\tValid\tstandard\t\t42518\tPPSV 23\t33\tMSD\tValid\tRisk\t\t44344\tPPSV 23\t33\t\tValid\tRisk\t\t\t\t\t\t\t\t\t7\t63999\t63999\t\tWhen elective splenectomy is being planned, PCV13 and/or PPSV23 vaccination should be completed at least 2 weeks before surgery or initiation of therapy.\tPneumococcal\t44344\tAll Valid: Forecast Test\t42615\t43482\tRecommended based on Condition\tAdd description\t4.0\n2016-UC-0169\tPatient is 9 years of age, has HIV infection, and has only received a dose of PPSV23 vaccine  but has not received a dose of the PCV 13 vaccine.\t39185\tM\t186\tHIV Infection\t\t\t\t\t\t\t\tNot Complete\t42522\tPPSV 23\t33\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t42578\t42578\t\t\tPneumococcal\t42522\tAll Valid: Forecast Test\t42615\t44231\tRecommended based on Condition\t4.2: Updated observation code from 155 to 186.\t4.2\n2016-UC-0170\tPatient is 9 years of age, has HIV infection,  and has received a dose of PPSV23 vaccine  and a dose of the PCV 13 vaccine 8 weeks later.\t39185\tM\t186\tHIV Infection\t\t\t\t\t\t\t\tNot Complete\t42522\tPPSV 23\t33\tMSD\tValid\trisk\t\t42578\tPCV 13\t133\tPFR\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t44348\t44348\t\t\tPneumococcal\t42578\tAll Valid: Forecast Test\t42615\t44231\tRecommended based on Condition\t4.2: Updated observation code from 155 to 186.\t4.2\n2016-UC-0171\tPatient is now 14 years of age, has HIV infection, and has received two doses ( one is booster dose 5 years later)  of PPSV23 and a dose of PCV13. \t39185\tM\t186\tHIV Infection\t\t\t\t\t\t\t\tNot Complete\t42522\tPPSV 23\t33\tMSD\tValid\trisk\t\t42578\tPCV 13\t133\tPFR\tValid\trisk\t\t44348\tPPSV 23\t33\tMSD\tValid\tRisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t4\t62927\t62927\t\t\tPneumococcal\t44348\tAll Valid: Forecast Test\t42615\t44231\tRecommended based on Condition\t4.2: Updated observation code from 155 to 186.\t4.2\n2016-UC-0172\tPatient is 22 years of age and has General malignant neoplasm and has received a dose of PPSV23 but not PCV.\t34498\tM\t156\tGeneralized malignant neoplasm\t\t\t\t\t\t\t\tNot Complete\t42603\tPPSV 23\t33\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t42968\t42968\t\t\tPneumococcal\t44586\tAll Valid: Forecast Test\t42615\t44586\tRecommended based on Condition\tUpdated earliest and recommended to 1 year per ACIP guidelines\t4.4\n2016-UC-0173\tPatient is 22 years of age with General malignant neoplasm and has received a dose of PPSV23 and a dose PCV 13 at a year later. \t34498\tM\t156\tGeneralized malignant neoplasm\t\t\t\t\t\t\t\tNot Complete\t42603\tPPSV 23\t33\tMSD\tValid\trisk\t\t42968\tPCV 13\t133\tPFR\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t44429\t44429\t\t\tPneumococcal\t42968\tAll Valid: Forecast Test\t42615\t43801\tRecommended based on Condition\tUpdated earliest and recommended forecast date to 5 years after most previous dose of PPSV23, added description\t4.1\n2016-UC-0174\tPatient is 27 years of age and has General malignant neoplasm, has received a dose of PPSV23, one  dose of  PCV13 and one dose  of PCV20\t34498\tM\t156\tGeneralized malignant neoplasm\t\t\t\t\t\t\t\tComplete\t42603\tPPSV 23\t33\tMSD\tValid\trisk\t\t42968\tPCV 13\t133\tPFR\tValid\trisk\t\t44641\tPCV 20\t216\tPFR\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\tAdults who have received PCV13 but have not completed their recommended pneumococcal vaccine series with PPSV23, one dose of PCV20 may be used if PPSV23 is not available.\tPneumococcal\t44641\tAll Valid: Forecast Test\t42615\t44642\tNot Recommended: Series Complete\tUpdated description to match current ACIP/CDC recommendations (01/22/22). Updated third dose by adding a PCV20 to complete the dose.\t4.4\n2016-UC-0175\tPatient is 14 years of age and has Persistent Component, properdin,  or Factor B deficiency, has previously received 2 doses of the PPSV23 vaccine   but has not received a dose of PCV13.\t37350\tF\t151\tPersistent complement, properdin, or factor B deficiency\t\t\t\t\t\t\t\tNot Complete\t40649\tPPSV 23\t33\tMSD\tValid\trisk\t\t42476\tPPSV 23\t33\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t42532\t42532\t\t\tPneumococcal\t42476\tAll Valid: Forecast Test\t42619\t43494\tRecommended based on Condition\tAdded description\t4.0\n2016-UC-0176\tPatient is 14 years of age and has Persistent Component, properdin,  or Factor B deficiency, has previously received 2 doses of the PPSV23 vaccine   and has received a dose of PCV13 vaccine 8 weeks later. \t37350\tF\t151\tPersistent complement, properdin, or factor B deficiency\t\t\t\t\t\t\t\tNot Complete\t40649\tPPSV 23\t33\tMSD\tValid\trisk\t\t42476\tPPSV 23\t33\tMSD\tValid\trisk\t\t42532\tPCV 13\t133\tPFR\tValid\tRisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t4\t61091\t61091\t\t\tPneumococcal\t42532\tAll Valid: Forecast Test\t42619\t43801\tRecommended based on Condition\tRemoved the past due date Added description\t4.1\n2016-UC-0177\tPatient is 25 years of age with  nephrotic syndrome, has previously received two doses of PPSV23 vaccine but has not received a dose of the PCV vaccine.\t31595\tM\t167\tNephrotic Syndrome\t\t\t\t\t\t\t\tNot Complete\t38932\tPPSV 23\t33\tMSD\tValid\trisk\t\t40758\tPPSV 23\t33\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t41124\t41124\t\t\tPneumococcal\t40758\tAll Valid: Forecast Test\t42619\t44596\tRecommended based on Condition\tUpdated earliest date\t4.4\n2016-UC-0178\tPatient is 25 years of age with nephrotic syndrome, and has received two doses of the PPSV vaccine and a dose of the PCV13 vaccine\t31595\tM\t167\tNephrotic Syndrome\t\t\t\t\t\t\t\tNot Complete\t38932\tPPSV 23\t33\tMSD\tValid\trisk\t\t40758\tPPSV 23\t33\tMSD\tValid\trisk\t\t41124\tPCV 13\t133\tPFR\tValid\tRisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t4\t55336\t55336\t55336\t\tPneumococcal\t41124\tAll Valid: Forecast Test\t42619\t43494\tRecommended based on Condition\tAdded Past Due date, added description\t4.0\n2016-UC-0179\tPatient is a traveler who plans to spend a month or longer in an endemic area and has experienced a severe allergic reaction after previous dose of Japanese Encephalitis vaccine.\t28469\tM\t082\tSevere allergic reaction after previous dose of Japanese Encephalitis\t\t165\tLonger-term (e.g., 1 month or more) travel to a JE-endemic area\t\t\t\t\tContraindicated\t42505\tJapanese Encephalitis, VC \t134\tVAL\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tJapanese Encephalitis\t42505\tAll Valid: Forecast Test\t42605\t43494\tNot recommended: contraindication\tUpdated to reflect an additional contraindication/observation.\t4.0\n2016-UC-0180\tPatient is a traveler who plans to spend a month in an endemic  area and has had an adverse reaction to a vaccine component of Japanese Encephalitis vaccine.\t29817\tF\t080\tAdverse reaction to vaccine component\t\t165\tLonger-term (e.g., 1 month or more) travel to a JE-endemic area\t\t\t\t\tContraindicated\t42309\tJapanese Encephalitis, VC \t134\tVAL\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tJapanese Encephalitis\t42309\tAll Valid: Forecast Test\t42605\t43494\tNot recommended: contraindication\tAdded description\t4.0\n2016-UC-0181\tPatient is person who frequently handles bats and has no previous history of the Rabies vaccination. \t28027\tM\t219\tPersons who frequently handle bats\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t28027\t28027\t\t\tRabies\t44687\tNo Doses Administered\t42607\t44715\tRecommended based on Condition\tUpdated test case name, Assessment date, date updated date, and general description to more closely align with the Rabies 20222 MMWR. 4.0 Added description\t4.4\n2016-UC-0182\tPatient is person who frequently handles bats and has received the first dose (on 05/06/2022) of the Rabies risk frequent vaccine series.\t28027\tM\t219\tPersons who frequently handle bats\t\t\t\t\t\t\t\tNot Complete\t44687\tRabies - IM Diploid cell culture\t175\tNOV\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t44694\t44694\t\t\tRabies\t44687\tAll Valid: Forecast Test\t42607\t44715\tRecommended based on interval\tUpdated test case name, first dose date, earliest and recommended dates.  Updated the assessment and date updated date as well as the general description to more closely align with the Rabies 20222 MMWR 4.0 Updated CVX code from 18 to 175/176, added description\t4.4\n2016-UC-0183\tPatient is a person who freqently handles bats and has received the second dose of the Rabies risk frequent vaccine series.\t28027\tM\t219\tPersons who frequently handle bats\t\t\t\t\t\t\t\tNot Complete\t44687\tRabies - IM Diploid cell culture\t175\tNOV\tValid\trisk\t\t44694\tRabies - IM Diploid cell culture\t175\tNOV\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t45425\t45425\t\t\tRabies\t44694\tAll Valid: Forecast Test\t42607\t44715\tRecommended based on interval\tUpdated test case name, first and second dose date, earliest and recommended dates.  Updated the assessment and date updated date as well as the general description to more closely align with the Rabies 20222 MMWR. 4.0 Updated Past Due date, added description\t4.4\n2016-UC-0184\tPatient is a person who frequently handles bats and has received  three doses of the Rabies risk frequent  vaccine series.\t28027\tM\t219\tPersons who frequently handle bats\t\t\t\t\t\t\t\tNot Complete\t44687\tRabies - IM Diploid cell culture\t175\tNOV\tValid\trisk\t\t44694\tRabies - IM Diploid cell culture\t175\tNOV\tValid\trisk\t\t45428\tRabies - IM Diploid cell culture\t175\tNOV\tValid\tRisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t4\t46158\t46158\t\tThe 2 year booster should only be given after a rabies antibody titer. The booster should be administered if the titer falls below 0.5 IU/mL.\tRabies\t45428\tAll Valid: Forecast Test\t42607\t44715\tRecommended based on interval\tUpdated test case name, first, second,  and third dose date, earliest and recommended dates.  Updated the assessment and date updated date as well as the general description to more closely align with the Rabies 20222 MMWR. 4.0 Updated Earliest and Recommended Date to reflect 2 years after the last dose date.\t4.4\n2016-UC-0186\tPatient is a person whose activities brings them into frequent contact with rabies virus or potentially rabid animals and has had an adverse reaction to Rabies vaccine  component\t31488\tF\t080\tAdverse reaction to vaccine component\t\t062\tPersons whose activities bring them into frequent contact with rabies virus or potentially rabid animals\t\t\t\t\tContraindicated\t42382\tRabies - IM Diploid cell culture\t175\tNOV\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tRabies\t42382\tAll Valid: Forecast Test\t42608\t43521\tNot recommended: contraindication\tUpdated to reflect an additional contraindication or observation, added a description.\t4.0\n2016-UC-0187\tPatient has experienced a severe allergic reaction to egg protein from the Yellow Fever vaccine.\t25187\tM\t101\tAllergic reaction to egg protein\t\t045\tTravel to country with a Yellow Fever vaccination entry requirement\t\t\t\t\tContraindicated\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tYellow Fever\t42442\tAll Valid: Forecast Test\t42604\t43521\tRecommended based on Condition\tAdded descriptions\t4.0\n2016-UC-0188\tPatient is a microbiology laboratorian who works frequently with S.Typhi Carrier and has received the Risk 4 dose vaccine series and the 5 year booster dose.\t28194\tF\t051\tMicrobiology laboratorians who work frequently with S. typhi\t\t\t\t\t\t\t\tNot Complete\t42561\tTyphoid capsular polysaccharide\t25\tPMC\tValid\trisk\t\t44387\tTyphoid capsular polysaccharide\t25\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t46213\t46213\t\tThis vaccine should be given at least 2 weeks before potential exposure.  Primary vaccination with live-attenuated Ty21a vaccine consists of one enteric-coated capsule taken on alternate days (day 0, 2, 4, and 6), for a total of four capsules. The capsules must be kept refrigerated (not frozen). Each capsule should be taken with cool water no warmer than 98.6°F (37.0°C), approximately 1 hour before a meal. All doses should be completed at least 1 week before potential exposure.\tTyphoid\t44387\tAll Valid: Forecast Test\t42611\t43528\tRecommended based on Condition\tUpdated to reflect an additional Condition/observation and updated booster dose to be administered at 5 years later. \t4.0\n2016-UC-0189\tPatient is a microbiology laboratorian who has experience a severe allergic reaction after previous dose of Typhoid vaccine\t26580\tM\t084\tSevere allergic reaction after previous dose of Typhoid\t\t051\tMicrobiology laboratorians who work frequently with S. typhi\t\t\t\t\tContraindicated\t42597\tTyphoid capsular polysaccharide\t101\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tTyphoid\t42597\tAll Valid: Forecast Test\t42604\t43528\tRecommended based on Condition\tUpdated to reflect an additional contraindication/observation.\t4.0\n2016-UC-0191\tPatient is a smoker, has asthma and has received a PCV 20 vaccine. \t34537\tM\t027\tAsthma\t\t042\tSmoke cigarettes\t\t\t\t\tComplete\t44593\tPCV\t216\tPFR\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tPneumococcal\t44593\tAll Valid: Forecast Test\t42604\t44593\tNot Recommended: Series Complete\tUpdated the test case first dose date, and CVX Code, etc per the ACIP/MMWR recommendation Jan 2022\t4.4\n2016-UC-0192\tPatient is a smoker, has diabetes, and asthma and has not received a PCV vaccine. \t23968\tM\t014\tDiabetes\t\t027\tAsthma\t\t042\tSmoke cigarettes\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t30908\t30908\t\t\tPneumococcal\t42608\tNo Doses Administered\t42608\t43528\tRecommended based on Condition\t\t4.0\n2016-UC-0193\tPatient is a smoker, has diabetes, and has asthma and has received the PPSV vaccine.\t23813\tM\t014\tDiabetes\t\t027\tAsthma\t\t042\tSmoke cigarettes\t\tNot Complete\t42563\tPPSV 23\t33\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t42928\t42928\t\t\tPneumococcal\t44586\tAll Valid: Forecast Test\t42608\t44586\tRecommended based on Condition\tUpdated test case to forecast a second dose, updated 8 weeks as Minimum Interval per the ACIP/MMWR recommendation Jan 2022\t4.4\n2016-UC-0194\tPatient is MSM, has HIV, is an illicit injection drug user, and has not been vaccinated with the Hep B vaccine.\t22687\tM\t036\tMen who have sex with men\t\t186\tHIV Infection\t\t041\tIllicit injection drug use\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t44602\t44602\t\t\tHepB\t44683\tNo Doses Administered\t42612\t44683\tRecommended based on Condition\tUpdated test came name, dob, assessment date to match more closely to the 2022 Adult Immunization Schedules\t4.4\n2016-UC-0195\tPatient is MSM, has HIV, and is an illicit injection drug user, and has received the first dose of the Hep B vaccine\t22687\tM\t036\tMen who have sex with men\t\t186\tHIV Infection\t\t041\tIllicit injection drug use\t\tNot Complete\t44607\tHep B, Adult \t43\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t44635\t44635\t\t\tHepB\t44607\tAll Valid: Forecast Test\t42612\t44683\tRecommended based on interval\tUpdated test case name, dob, administration dose #2 date, eetc\t4.4\n2016-UC-0196\tPatient is MSM, has HIV,  is an illicit injection drug user, and has received the second dose of Hep B\t22687\tM\t036\tMen who have sex with men\t\t186\tHIV Infection\t\t041\tIllicit injection drug use\t\tNot Complete\t44607\tHep B, Adult \t43\tMSD\tValid\trisk\t\t44635\tHep B, Adult \t43\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t44719\t44788\t\t\tHepB\t44635\tAll Valid: Forecast Test\t42612\t44915\tRecommended based on interval\tUpdated test case name, dob, administration dose for doses 1 and #2 date, forecast dates, tc\t4.4\n2016-UC-0197\tPatient is MSM, has HIV,  is an illicit injection drug user, and has received all three doses of Hep B\t22687\tM\t036\tMen who have sex with men\t\t186\tHIV Infection\t\t041\tIllicit injection drug use\t\tComplete\t44607\tHep B, Adult \t43\tMSD\tValid\trisk\t\t44635\tHep B, Adult \t43\tMSD\tValid\trisk\t\t44757\tHep B, Adult \t43\tMSD\tValid\tRisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tHepB\t44757\tAll Valid: Forecast Test\t42612\t44683\tNot Recommended: Series Complete\tUpdated test case dob, administration dose #3, assessement date to match the 2022 Adult Immunization Schedules\t4.4\n2016-UC-0198\tPatient is 39 years of age,  a microbiologist who is frequently exposed to Neisseria meningitidis, and  who plans to travel to countries where meningococcal disease is endemic. \t28319\tF\t050\tMicrobiologists routinely exposed to Neisseria meningitidis\t\t164\tTravel to or are residents of countries in which meningococcal disease is hyperendemic or epidemic\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t29049\t29049\t\t\tMeningococcal\t42584\tNo Doses Administered\t42584\t43538\tRecommended based on Condition\tUpdated to reflect an Earliest and Recommended data of 07/13/79.07/13/1979, added description.\t4.0\n2016-UC-0200\tPatient is using dialysis and has had a previous severe allergic reaction to vaccine ingredient  yeast  in the Hep B(Energix B) vaccine. \t18016\tM\t097\tSevere allergic reaction after previous dose of Hepatitis B\t\t032\tDialysis patient\t\t\t\t\tContraindicated\t42141\tHep B, Adult\t43\tSKB\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tHepB\t42412\tAll Valid: Forecast Test\t42608\t43538\tNot recommended: contraindication\tUpdated to reflect an additional contraindication/observation. \t4.0\n2016-UC-0201\tPatient is a travelling internationaly with possible contact with animals in an area where rabies is enzootic and immediate access to appropriate medical care might be limited and has been administered four doses (before 05/06/2022) of the Rabies vaccine\t28935\tM\t144\tInternational travel with possible contact with animals in areas where rabies is enzootic and immediate access to appropriate medical care might be limited\t\t\t\t\t\t\t\tComplete\t44584\tRabies - IM fibroblast culture\t176\tPMC\tValid\trisk\t\t44591\tRabies - IM fibroblast culture\t176\tPMC\tValid\trisk\t\t44605\tRabies - IM fibroblast culture\t176\tPMC\tValid\tRisk\t\t44626\tRabies - IM fibroblast culture\t176\tPMC\tValid\tRisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tRabies\t44626\tAll Valid: Forecast Test\t42608\t44715\tNot Recommended: Series Complete\tUpdated test case name, first, second, third, and fourth dose dates, date updated, assessment date to align more closely with the MMWR for Rabies 2022. 4.0 Updated to reflect an additional contraindication/observation.\t4.4\n2016-UC-0202\tPatient is pregnant, and does not have evidence of immunity from Rubella disease.\t31199\tF\t007\tPregnant\t\t\t\t\t\t\t\tContraindicated\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\tPregnant women who do not have evidence of immunity should receive MMR vaccine upon completion or termination of pregnancy and before discharge from the health care facility.\tMMR\t42591\tNo Doses Administered\t42591\t43538\tNot recommended: contraindication\tadded description\t4.0\n2016-UC-0203\tPatient is seeking protection, and has had a severe allergic reaction after previous dose of Meningococcal B vaccine.\t34712\tM\t116\tSevere allergic reaction after previous dose of Meningococcal B\t\t001\tPatient seeks protection\t\t\t\t\tContraindicated\t42549\tmeningococcal B, OMV\t163\t\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tMenB\t42549\tAll Valid: Forecast Test\t42632\t43538\tNot recommended: contraindication\tUpdated to reflect an additional contraindication/observation. Added description\t4.0\n2017-UC-0001\tPatient is 9 years of age, female, with a history of sexual assault, and has received two previous doses of HPV vaccine at least 6 months apart.\t38910\tF\t169\tHistory of sexual abuse or assault\t\t\t\t\t\t\t\tComplete\t42197\t9vHPV\t165\tMSD\tValid\trisk\t\t42392\t9vHPV\t165\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tHPV\t42392\tAll Valid: Forecast Test\t42744\t43538\tRecommended based on Condition\tUpdated to reflect an additional Condition/observation.\t4.0\n2017-UC-0002\tPatient is 15 years of age, with a history of immunosuppressive therapy, and has not received any previous doses of the HPV vaccine.\t37165\tM\t158\tImmunosuppressive therapy\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t40452\t41183\t41940\t\tHPV\t42738\tNo Doses Administered\t42745\t43801\tRecommended based on Condition\tadded a past due date.  Updated to reflect an additional Condition/observation.  Added description\t4.1\n2017-UC-0003\tPatient is 15 years of age,  with a immunosuppressive therapy and has received the first dose of the HPV vaccine 3 dose series\t37165\tM\t158\tImmunosuppressive therapy\t\t\t\t\t\t\t\tNot Complete\t42743\t9vHPV\t165\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t42771\t42771\t42854\t\tHPV\t42743\tAll Valid: Forecast Test\t42768\t43801\tRecommended based on Condition\tAdded past due date Added description\t4.1\n2017-UC-0004\tPatient is 15 years of age, with a immunosuppressive therapy and has received the first and second dose of the 3 dose  HPV vaccine series.\t37165\tM\t158\tImmunosuppressive therapy\t\t\t\t\t\t\t\tNot Complete\t42743\t9vHPV\t165\tMSD\tValid\trisk\t\t42771\t9vHPV\t165\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t42894\t42924\t42982\t\tHPV\t42924\tAll Valid: Forecast Test\t42768\t43542\tRecommended based on Condition\tAdded description\t4.0\n2017-UC-0005\tPatient is 15 years of age, with a history of immunosuppressive therapy, and has received all three recommended doses of  the HPV vaccine series.\t37165\tM\t158\tImmunosuppressive therapy\t\t\t\t\t\t\t\tComplete\t42743\t9vHPV\t165\tMSD\tValid\trisk\t\t42771\t9vHPV\t165\tMSD\tValid\trisk\t\t42894\t9vHPV\t165\tMSD\tValid\tRisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tHPV\t43008\tAll Valid: Forecast Test\t42768\t43542\tRecommended based on Condition\tAdded description\t4.0\n2017-UC-0007\tPatient is 11 years of age, with generalized malignant neoplasm, and has not received any previous does of the HPV vaccine.\t38505\tF\t156\tGeneralized malignant neoplasm\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t41792\t42523\t43280\t\tHPV\t42583\tNo Doses Administered\t42768\t43801\tRecommended based on Condition\tAdded past due date Added description\t4.1\n2017-UC-0008\tPatient is 11 years of age, with generalized malignant neoplasm and has received the first dose of the HPV 3 dose vaccine series.\t38505\tF\t156\tGeneralized malignant neoplasm\t\t\t\t\t\t\t\tNot Complete\t42583\t9vHPV\t165\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t42611\t42611\t42694\t\tHPV\t42583\tAll Valid: Forecast Test\t42768\t43532\tRecommended based on Condition\tAdded description\t4.0\n2017-UC-0009\tPatient is 11 years of age, with generalized malignant neoplasm and has received the second dose of the HPV vaccine at 4 weeks later.\t38505\tF\t156\tGeneralized malignant neoplasm\t\t\t\t\t\t\t\tNot Complete\t42583\t9vHPV\t165\tMSD\tValid\trisk\t\t42611\t9vHPV\t165\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t42736\t42767\t42822\t\tHPV\t42611\tAll Valid: Forecast Test\t42768\t43801\tRecommended based on Condition\tUpdated earliest, recommended, and past due dates Added description\t4.1\n2017-UC-0010\tPatient is 11 years of age, with generalized malignant neoplasm and has received all three doses of the HPV 3 dose vaccine series.\t38505\tF\t156\tGeneralized malignant neoplasm\t\t\t\t\t\t\t\tComplete\t42583\t9vHPV\t165\tMSD\tValid\trisk\t\t42611\t9vHPV\t165\tMSD\tValid\trisk\t\t42758\t9vHPV\t165\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tHPV\t42758\tAll Valid: Forecast Test\t42768\t43550\tRecommended based on Condition\tAdded description\t4.0\n2017-UC-0011\tPatient is an adult with persistent complement component deficiencies and has not received any previous doses of the Men B vaccine\t34944\tM\t151\tPersistent complement, properdin, or factor B deficiency\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t38597\t38597\t\t\tMenB\t42796\tNo Doses Administered\t42814\t43550\tRecommended based on Condition\tAdded description \t4.0\n2017-UC-0012\tPatient is an adult with persistent complement component deficiencies and has received the first dose of the 2 dose Men B (Bexsero) vaccine\t34944\tM\t151\tPersistent complement, properdin, or factor B deficiency\t\t\t\t\t\t\t\tNot Complete\t42796\tmeningococcal B, OMV\t163\tNOV\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t42824\t42824\t\t\tMenB\t42796\tAll Valid: Forecast Test\t42814\t43801\tRecommended based on Condition\tUpdated recommended date from 03/30/3017 to 03/30/2017  Added description\t4.1\n2017-UC-0013\tPatient is an adult with persistent complement component deficiencies and has received the second dose of the 2 dose Men B (Bexsero) vaccine\t34944\tM\t151\tPersistent complement, properdin, or factor B deficiency\t\t\t\t\t\t\t\tNot Complete\t42796\tmeningococcal B, OMV\t163\tNOV\tValid\trisk\t\t42980\tmeningococcal B, OMV\t163\tNOV\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t43345\t43345\t\t\tMenB\t43345\tAll Valid: Forecast Test\t42814\t43879\tRecommended based on Condition\t4.2: updated test case to add booster dose base on the immunization schedule Feb 2020.\t4.2\n2017-UC-0014\tPatient is 38 years of age, a microbiologist  who is routinely exposed to Neisseria Meningitis, and who has received the Risk 1 dose and the 5 years booster dose   for Men ACWY \t28319\tF\t050\tMicrobiologists routinely exposed to Neisseria meningitidis\t\t\t\t\t\t\t\tNot Complete\t40372\tMeningococcal, MCV4P\t114\tPMC\tValid\trisk\t\t42198\tMeningococcal, MCV4P\t114\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t44025\t44025\t\t\tMeningococcal\t42198\tAll Valid: Forecast Test\t42814\t43550\tRecommended based on Condition\tAdded description\t4.0\n2017-UC-0015\tPatient is 35 years of age and is traveling to a country that has active cholera transmission.\t29999\tM\t008\tTravel to an area of active cholera transmission\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t36573\t36573\t\t\tCholera\t42934\tNo Doses Administered\t42934\t43550\tRecommended based on Condition\tAdded description\t4.0\n2017-UC-0016\tPatient is 35 years of age and is traveling to a country that has active cholera transmission and has received the Cholera 1-dose series.\t29999\tM\t008\tTravel to an area of active cholera transmission\t\t\t\t\t\t\t\tComplete\t42934\tCholera\t174\tPAX\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tCholera\t42934\tAll Valid: Forecast Test\t42934\t43550\tRecommended based on Condition\tAdded description\t4.0\n2017-UC-0017\tPatient is 28 years of age and has a severe allergic reaction after previous dose of the Cholera vaccine.\t32721\tM\t119\tSevere allergic reaction after previous dose of cholera\t\t008\tTravel to an area of active cholera transmission\t\t\t\t\tContraindicated\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tCholera\t42948\tNo Doses Administered\t42969\t43801\tNot recommended: contraindication\tAdded Observation Code 008, updated 080 to 119 Added description\t4.1\n2018-UC-0001\tPatient is 15 years of age with persistent complement and has received the second dose, of the Risk 3 dose Men B vaccine series, at greater than or equal to 6 months after the first administered dose.\t37690\tM\t151\tPersistent complement, properdin, or factor B deficiency\t\t\t\t\t\t\t\tNot Complete\t43181\tmeningococcal B, recombinant \t162\tPFR\tValid\trisk\t\t43365\tmeningococcal B, recombinant\t162\tPFR\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t43730\t43730\t\t\tMenB\t43365\tAll Valid: Forecast Test\t43392\t43868\tRecommended based on Condition\t4.2: Updated test case to forecast booster dose.\t4.2\n2018-UC-0002\tPatient is 7 years has persistent complement and has received the first dose of the MenACWY vaccine at 9 months, second dose at 7 years.\t40545\tM\t151\tPersistent complement, properdin, or factor B deficiency\t\t\t\t\t\t\t\tNot Complete\t40818\tMeningococcal, MCV4O \t136\tNOV\tValid\trisk\t\t43102\tMeningococcal, MCV4O \t136\tNOV\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t44928\t44928\t\t\tMeningococcal\t43102\tAll Valid: Forecast Test\t43402\t43801\tRecommended based on Condition\tRemoved past due date added description\t4.1\n2018-UC-0004\tPatient is 60 years of age with chronic liver disease and has not received a dose of Hep B vaccine. \t22455\tF\t015\tChronic liver disease\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t44370\t44370\t\t\tHepB\t44683\tNo Doses Administered\t43451\t44683\tRecommended based on Condition\tUpdated the forecast earliest date.\t4.4\n2018-UC-0005\tPatient is 60 years of age with chronic liver disease  and has received the first dose in the Risk 2 (Heplisav) dose Hep B vaccine. \t22455\tF\t015\tChronic liver disease\t\t\t\t\t\t\t\tNot Complete\t44619\tHepB-CpG \t189\tDVX\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t44647\t44647\t44674\t\tHepB\t44619\tAll Valid: Forecast Test\t43451\t44676\tRecommended based on interval\tUpdated test case  first dose date, assessment date, etc per updates to the 2022 Adult Immunization Schedules\t4.4\n2018-UC-0006\tPatient is 60 years of age with chronic liver disease  and has received the first and second dose in the Risk 2 dose(Heplisav)  Hep B vaccine.\t22455\tF\t015\tChronic liver disease\t\t\t\t\t\t\t\tComplete\t44619\tHepB-CpG \t189\tDVX\tValid\trisk\t\t44647\tHepB-CpG \t189\tDVX\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tHepB\t44647\tAll Valid: Forecast Test\t43451\t44676\tNot Recommended: Series Complete\tUpdated test case first and second dose date, assessment date, etc per updates to the 2022 Adult Immunization Schedules\t4.4\n2019-UC-0001\tPatient is 32 years of age and traveling to an endemic area during JE Transmission, and has received the two primary doses and the booster dose.\t30569\tM\t165\tLonger-term (e.g., 1 month or more) travel to a JE-endemic area\t\t\t\t\t\t\t\tComplete\t42488\tJapanese Encephalitis, VC \t134\tVAL\tValid\trisk\t\t42515\tJapanese Encephalitis, VC\t134\tVAL\tValid\trisk\t\t43665\tJapanese Encephalitis, VC\t134\tVAL\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tJapanese Encephalitis\t43665\tAll Valid: Forecast Test\t43525\t43666\tRecommended based on Condition\tAdded booster dose information\t4.0\n2019-UC-0002\tPatient is 2 years of age and has been recently diagnosed with chronic renal failure and has not received any dose of the PCV vaccine  \t42854\tF\t066\tChronic renal failure\t43644\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t43584\t43584\t\t\tPneumococcal\t43647\tNo Doses Administered\t43656\t43839\tRecommended based on Condition\t4/2: Added observation date.\t4.2\n2019-UC-0003\tPatient is 2 years of age and has been recently diagnosed  with chronic renal failure and has received the first  dose of the PCV Vaccine.\t42854\tF\t066\tChronic renal failure\t43644\t\t\t\t\t\t\tNot Complete\t43647\tPCV 13\t133\t\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t43703\t43703\t\t\tPneumococcal\t43647\tAll Valid: Forecast Test\t43656\t43839\tRecommended based on Condition\t4.2: Added observation date.\t4.2\n2019-UC-0004\tPatient is 2 years of age and has been recently diagnosed with chronic renal failure and has received two doses of the PCV vaccine.\t42854\tF\t066\tChronic renal failure\t43644\t\t\t\t\t\t\tNot Complete\t43647\tPCV 13\t133\t\tValid\trisk\t\t43703\tPCV 13\t133\t\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t43759\t43759\t\t\tPneumococcal\t43703\tAll Valid: Forecast Test\t43656\t43839\tRecommended based on Condition\t4.2: Added observation date Updated description.\t4.2\n2019-UC-0005\tPatient is 2 years of age and has been recently diagnosed with chronic renal failure and has received two doses of the PCV vaccine and a dose of the PPSV23 vaccine.\t42854\tF\t066\tChronic renal failure\t43644\t\t\t\t\t\t\tNot Complete\t43647\tPCV 13\t133\t\tValid\trisk\t\t43703\tPCV 13\t133\t\tValid\trisk\t\t43759\tPPSV 23\t33\t\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t4\t45586\t45586\t\t\tPneumococcal\t43759\tAll Valid: Forecast Test\t43656\t43839\tRecommended based on Condition\t4.2: Added observation date and  updating general description\t4.2\n2019-UC-0007\tPatient is 43 years of age,  a microbiologist who is frequently exposed to Neisseria meningitidis, who has received two dose of the Meningococcal B vaccine and the one year booster dose. \t28026\tF\t050\tMicrobiologists routinely exposed to Neisseria meningitidis\t\t\t\t\t\t\t\tNot Complete\t43239\tmeningococcal B, OMV\t163\tNOV\tValid\trisk\t\t43267\tmeningococcal B, OMV\t163\tNOV\tValid\trisk\t\t43881\tmeningococcal B, OMV\t163\tNOV\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t4\t44612\t44612\t45341\t\tMenB\t43881\tAll Valid: Forecast Test\t43729\t43886\tRecommended based on Condition\t4.2: added booster dose information per the new immunization schedule release Feb 2020\t4.2\n2019-UC-0008\tPatient is 65 years with Cochlear implants and no doses of PCV or PPSV23.\t20826\tM\t011\tCochlear implants\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t27765\t27765\t\t\tPneumococcal\t44593\tNo Doses Administered\t43684\t44593\tRecommended based on Condition\tUpdated the age of the patient to align the test case with current MMWR recommendations\t4.4\n2019-UC-0009\tPatient is 65 years with Cochlear implants with a PCV20.\t20826\tM\t011\tCochlear implants\t\t\t\t\t\t\t\tComplete\t44593\tPCV20\t216\tPFR\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tPneumococcal\t44593\tAll Valid: Forecast Test\t43684\t44593\tNot Recommended: Series Complete\tUpdated test case first dose date to reflect changes to Pneumo MMWR 01/2022\t4.4\n2019-UC-0010\tPatient is 65 years with Cochlear implants and has received PCV 13 and PPSV dose\t19942\tM\t011\tCochlear implants\t\t\t\t\t\t\t\tComplete\t43693\tPREVNAR 13\t133\tPFR\tValid\trisk\t\t44049\tPPSV 23\t33\tPFR\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tPneumococcal\t44049\tAll Valid: Forecast Test\t43684\t44087\tRecommended based on Condition\tUpdated test case scenario.\t4.1\n2019-UC-0011\tPatient is an adult that is greater than or equal to 60 years and is seeking protection for Hep B and has no history of the vaccine\t22661\tF\t001\tPatient seeks protection\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t44576\t44576\t\tAnyone age 60 years or older who does not meet risk-based recommendations may still receive Hepatitis B vaccination\tHepB\t44619\tNo Doses Administered\t43805\t44648\tRecommended based on Condition\tUpdated test case patient age per updates to the 2022 Adult Immunization Schedules\t4.4\n2019-UC-0012\tPatient is an adult that is greater than or equal to 60 years and is seeking protection for Hep B  and has received a first dose as the Heplisav vaccine.\t22661\tF\t001\tPatient seeks protection\t\t\t\t\t\t\t\tNot Complete\t44619\tHepB-CpG \t189\tDVX\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t44647\t44647\t44674\tAnyone age 60 years or older who does not meet risk-based recommendations may still receive Hepatitis B vaccination\tHepB\t44619\tAll Valid: Forecast Test\t43805\t44648\tRecommended based on interval\tUpdated test case patient age per the 2022 Adult Immunization Schedules\t4.4\n2019-UC-0013\tPatient is an adult that is greater than or equal to 60 years and is seeking protection for Hep B and has received two doses.\t22661\tF\t001\tPatient seeks protection\t\t\t\t\t\t\t\tNot Complete\t44619\tHepB-CpG \t189\tDVX\tValid\trisk\t\t44647\tHepB Adult\t43\t\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t44731\t44800\t\tAnyone age 60 years or older who does not meet risk-based recommendations may still receive Hepatitis B vaccination\tHepB\t44647\tAll Valid: Forecast Test\t43805\t44648\tRecommended based on interval\tUpdated test case patient age and first and second dose dates per  the 2022 Adult Immunization Schedules\t4.4\n2019-UC-0014\tPatient is an adult that is greater than or equal to 60 years, and is seeking protection for Hep B and has received three doses.\t22661\tF\t001\tPatient seeks protection\t\t\t\t\t\t\t\tNot Complete\t44619\tHep B\t189\tDVX\tValid\trisk\t\t44647\tHep B Adult\t43\tMSD\tValid\trisk\t\t44675\tHep B Adult\t43\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t4\t44703\t44703\t44730\tAnyone age 60 years or older who does not meet risk-based recommendations may still receive Hepatitis B vaccination\tHepB\t44675\tAll Valid: Forecast Test\t43805\t44675\tRecommended based on interval\tUpdated test case patient age and first, second, and third dose dates per the 2022 Adult Immunization Schedules\t4.4\n2019-UC-0015\tPatient is an adult that is greater than or equal to 60 years, and is seeking protection for Hep B and has received four doses.\t22661\tF\t001\tPatient seeks protection\t\t\t\t\t\t\t\tComplete\t44619\tHepB-CpG \t189\tDVX\tValid\trisk\t\t44647\tHep B Adult\t43\tMSD\tValid\trisk\t\t44675\tHep B Adult\t43\tMSD\tValid\trisk\t\t44703\tHepB-CpG\t189\tDVX\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\tAnyone age 60 years or older who does not meet risk-based recommendations may still receive Hepatitis B vaccination\tHepB\t44703\tAll Valid: Forecast Test\t43805\t44648\tNot Recommended: Series Complete\tUpdated test case patient age and all four dose dates per  the 2022 Adult Immunization Schedules\t4.4\n2020-UC-0001\tPatient is 13 years of age, has anatomical or functional asplenia, has received two primary doses and the one year booster dose of the Men B vaccine.\t38804\tF\t160\tAnatomical or functional asplenia\t\t\t\t\t\t\t\tNot Complete\t42457\tmeningococcal B, OMV\t163\tNOV\tValid\trisk\t\t42641\tmeningococcal B, OMV\t163\tNOV\tValid\trisk\t\t43881\tmeningococcal B, OMV\t163\tNOV\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t4\t44612\t44612\t45341\t\tMenB\t43881\tAll Valid: Forecast Test\t43886\t43886\tRecommended based on Condition\n2020-UC-0002\tPatient is an adult with persistent complement component deficiencies and has received the primary 2 dose Bexsero vaccine and the one year booster dose.\t34944\tF\t151\tPersistent complement, properdin, or factor B deficiency\t\t\t\t\t\t\t\tNot Complete\t42796\tmeningococcal B, OMV \t163\tNOV\tValid\trisk\t\t42980\tmeningococcal B, OMV\t163\tNOV\tValid\trisk\t\t43881\tmeningococcal B, OMV\t163\tNOV\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t4\t44612\t44612\t45341\t\tMenB\t43881\tAll Valid: Forecast Test\t43886\t43886\tRecommended based on Condition\n2020-UC-0004\tPatient is an adolescent with anatomical or functional asplenia and has received the third dose of the Risk 3 dose Men B vaccine at 4 months.\t39570\tF\t160\tAnatomical or functional asplenia\t\t\t\t\t\t\t\tNot Complete\t43953\tmeningococcal B, recombinant\t162\tPFR\tValid\trisk\t\t43981\tmeningococcal B, recombinant\t162\tPFR\tValid\trisk\t\t44104\tmeningococcal B, recombinant\t162\tPFR\tValid\tRisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t4\t44469\t44469\t\t\tMenB\t44104\tAll Valid: Forecast Test\t43923\t43923\tRecommended based on Condition\n2021-UC-0001\tPatient is a healthcare worker at a federally designated Ebola Treatment Center in the U.S. and has not received a dose of the Ebola vaccine.\t33923\tF\t183\tHealth care personnel at federally designated Ebola treatment center in U.S. \t\t\t\t\t\t\t\tNot Complete\t-\t\t\t\t\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t40497\t40497\t\t\tEbola\t44355\tNo Doses Administered\t44355\t44355\tRecommended based on Condition\n2021-UC-0002\tPatient is a healthcare worker at a federally designated Ebola Treatment Center in the U.S. and has received a dose of the Ebola vaccine.\t33923\tF\t183\tHealth care personnel at federally designated Ebola treatment center in U.S. \t\t\t\t\t\t\t\tComplete\t44355\tEbola Zaire vaccine, live\t204\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tEbola\t44355\tAll Valid: Forecast Test\t44355\t44355\tNot Recommended: Patient Complete\n2021-UC-0003\tPatient with HIV/AIDS, is severely immunocompromised and hasn't received any doses of the COVID-19 vaccine\t40043\tM\t154\tHIV/AIDS - severely immunocompromised\t\t\t\t\t\t\t\tNot Complete\t-\t\t\t\t\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t44426\t44426\t\tA patients clinical team is best positioned to determine the degree of immune compromise and appropriate timing of vaccination.  Factors to consider in assessing the general level of immune competence in a patient include disease severity, duration, clinical stability, complications, comorbidities, and any potentially immune-suppressing treatment.\tCOVID-19\t44426\tNo Doses Administered\t44425\t\tRecommended based on Condition\t\t4.3\n2021-UC-0004\tPatient is an adult who has HIV/AIDS, is severely immunocompromised, and has received the first dose of the Moderna COVID-19 vaccine.\t30042\tM\t154\tHIV/AIDS - severely immunocompromised\t\t\t\t\t\t\t\tNot Complete\t44329\tCOVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose\t207\tMOD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t44357\t44357\t44371\tA patients clinical team is best positioned to determine the degree of immune compromise and appropriate timing of vaccination.  Factors to consider in assessing the general level of immune competence in a patient include disease severity, duration, clinical stability, complications, comorbidities, and any potentially immune-suppressing treatment.\tCOVID-19\t44329\tAll Valid: Forecast Test\t44425\t\tRecommended based on interval\t\t4.3\n2021-UC-0005\tPatient is an adult with HIV/AIDS, is severely immunocompromised, and has received the first and second dose of the Moderna COVID-19 vaccine.\t30042\tM\t154\tHIV/AIDS - severely immunocompromised\t\t\t\t\t\t\t\tNot Complete\t44329\tCOVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose\t207\tMOD\tValid\trisk\t\t44357\tCOVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL\t207\tMOD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t44385\t44385\t44399\tA patients clinical team is best positioned to determine the degree of immune compromise and appropriate timing of vaccination.  Factors to consider in assessing the general level of immune competence in a patient include disease severity, duration, clinical stability, complications, comorbidities, and any potentially immune-suppressing treatment.\tCOVID-19\t44357\tAll Valid: Forecast Test\t44425\t\tRecommended based on Condition\t\t4.3\n2021-UC-0006\tPatient is an adult with HIV/AIDS and is severely immunocompromised and has received three doses of the Moderna COVID-19 vaccine.\t30042\tM\t154\tHIV/AIDS - severely immunocompromised\t\t\t\t\t\t\t\tNot Complete\t44329\tCOVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose\t207\tMOD\tValid\trisk\t\t44357\tCOVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose\t207\tMOD\tValid\trisk\t\t44516\tCOVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose\t207\tMOD\tValid\tRisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t4\t44572\t44572\t\tA patients clinical team is best positioned to determine the degree of immune compromise and appropriate timing of vaccination.  Factors to consider in assessing the general level of immune competence in a patient include disease severity, duration, clinical stability, complications, comorbidities, and any potentially immune-suppressing treatment.\tCOVID-19\t44809\tAll Valid: Forecast Test\t44425\t44879\tRecommended based on interval\tUpdated test case to add the forecasting of a booster dose at Recommended interval of 8 weeks instead of 3 months based on current ACIP recommendations (Sept 2022)\t4.4\n2021-UC-0007\tPatient is an adult who is receiving active treatment for solid tumors and has received a dose of the Janssen Covid-19 vaccine.\t34265\tF\t189\tActive treatment for solid tumors\t\t\t\t\t\t\t\tNot Complete\t44344\tSARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL\t212\tJSN\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t44372\t44372\t44385\tA patients clinical team is best positioned to determine the degree of immune compromise and appropriate timing of vaccination.  Factors to consider in assessing the general level of immune competence in a patient include disease severity, duration, clinical stability, complications, comorbidities, and any potentially immune-suppressing treatment.\tCOVID-19\t44344\tAll Valid: Forecast Test\t44425\t44620\tRecommended based on interval\tUpdated test case to add the forecasting of a booster dose based on ACIP recommendations\t4.4\n2021-UC-0008\tPatient is an adolescent and a transplant recipient and has received two doses of the Pfizer Covid-19 vaccine\t39888\tF\t157\tTransplantation\t43493\t\t\t\t\t\t\tNot Complete\t44336\tCOVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose \t208\tPFR\tValid\trisk\t\t44357\tCOVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose \t208\tPFR\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t44385\t44385\t\tA patients clinical team is best positioned to determine the degree of immune compromise and appropriate timing of vaccination.  Factors to consider in assessing the general level of immune competence in a patient include disease severity, duration, clinical stability, complications, comorbidities, and any potentially immune-suppressing treatment.\tCOVID-19\t44608\tAll Valid: Forecast Test\t44425\t44608\tRecommended based on interval\tAdded an observation date for the transplantation.  Updated the past due date.\t4.4\n2021-UC-0009\tPatient is an adolescent and a transplant recipient and has received three doses of a Covid-19 vaccine\t39888\tF\t157\tTransplantation\t43493\t\t\t\t\t\t\tNot Complete\t44336\tCOVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose \t208\tPFR\tValid\trisk\t\t44357\tCOVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose \t208\tPFR\tValid\trisk\t\t44573\tCovid-19 Pfizer\t208\tPFR\tValid\tRisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t4\t44629\t44629\t\tA patients clinical team is best positioned to determine the degree of immune compromise and appropriate timing of vaccination.  Factors to consider in assessing the general level of immune competence in a patient include disease severity, duration, clinical stability, complications, comorbidities, and any potentially immune-suppressing treatment.\tCOVID-19\t44814\tAll Valid: Forecast Test\t44425\t44814\tRecommended based on interval\tUpdated to add booster dose at 8 weeks instead of 3 months. Also added Observation date for transplantation.\t4.4\n2021-UC-0015\tPatient is an adult with HIV/AIDS and is severely immunocompromised and has received four doses of a COVID-19 vaccine.\t30042\tM\t154\tHIV/AIDS - severely immunocompromised\t\t\t\t\t\t\t\tNot Complete\t44329\tCOVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose\t207\tMOD\tValid\trisk\t\t44357\tCOVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose\t207\tMOD\tValid\trisk\t\t44424\tCOVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose\t207\tMOD\tValid\tRisk\t\t44577\tCOVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL or 50 mcg/.25mL\t207\tMOD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t5\t44633\t44633\t\t\tCOVID-19\t44811\tAll Valid: Forecast Test\t44497\t44879\tRecommended based on interval\t\t4.4\n2021-UC-0016\tPatient is an adolescent and a transplant recipient and has received four doses of a Covid-19 vaccine\t39888\tF\t157\tTransplantation\t43493\t\t\t\t\t\t\tNot Complete\t44336\tCOVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose \t208\tPFR\tValid\trisk\t\t44357\tCOVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose \t208\tPFR\tValid\trisk\t\t44573\tCOVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose \t208\tPFR\tValid\tRisk\t\t44663\tCOVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose \t208\tPFR\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t5\t44719\t44719\t\t\tCOVID-19\t44814\tAll Valid: Forecast Test\t44593\t44879\tRecommended based on interval\tAdded Observation code for transplantation.\t4.4\n2022-UC-0001\tPatient is almost 9 years of age and has a positive test result for Dengue\t41317\tM\t211\tEvidence of previous dengue infection and living in areas where dengue is endemic\t44564\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t44604\t44604\t\t\tDengue\t44565\tNo Doses Administered\t44565\t44565\tRecommended based on Condition\t\t4.4\n2022-UC-0002\tPatient is 9 years of age and has a positive test result for Dengue and has received a first dose of the vaccine.\t41317\tM\t211\tEvidence of previous dengue infection and living in areas where dengue is endemic\t44564\t\t\t\t\t\t\tNot Complete\t44610\tDengue Fever\t56\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t44791\t44791\t\t\tDengue\t44610\tAll Valid: Forecast Test\t44565\t44565\tRecommended based on interval\t\t4.4\n2022-UC-0003\tPatient is 9 years of age and has a positive test result for Dengue and has received a second dose of the Denvaxia vaccine.\t41317\tM\t211\tEvidence of previous dengue infection and living in areas where dengue is endemic\t44564\t\t\t\t\t\t\tNot Complete\t44610\tDengue Fever\t56\tPMC\tValid\trisk\t\t44791\tDengue Fever\t56\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t44975\t44975\t\t\tDengue\t44791\tAll Valid: Forecast Test\t44571\t44571\tRecommended based on interval\t\t4.4\n2022-UC-0004\tPatient is 10 years of age and has a positive test result for Dengue and has received all three doses of the Denvaxia vaccine.\t41317\tM\t211\tEvidence of previous dengue infection and living in areas where dengue is endemic\t44564\t\t\t\t\t\t\tComplete\t44610\tDengue Fever\t56\tPMC\tValid\trisk\t\t44791\tDengue Fever\t56\tPMC\tValid\trisk\t\t44975\tDengue Fever\t56\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tDengue\t44975\tAll Valid: Forecast Test\t44571\t44571\tNot Recommended: Series Complete\t\t4.4\n2022-UC-0005\tPatient is 8 years of age and has a positive test result for Dengue.\t41465\tF\t211\tEvidence of previous dengue infection and living in areas where dengue is endemic\t44575\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t44752\t44752\t\t\tDengue\t44610\tNo Doses Administered\t44575\t44575\tRecommended based on age\t\t4.4\n2022-UC-0006\tPatient is an adult with Hodgkin's disease and has not received any doses of the Zoster vaccine\t37669\tM\t180\tHodgkin's disease\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t44609\t44609\t\t\tZoster\t44620\tNo Doses Administered\t44621\t44621\tRecommended based on Condition\t\t4.4\n2022-UC-0007\tPatient is an adult with Hodgkin's disease and has been administered the first dose of the Zoster vaccine\t37669\tM\t180\tHodgkin's disease\t\t\t\t\t\t\t\tNot Complete\t44620\tZoster Recombinant\t187\tSKB\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t44648\t44676\t44859\t\tZoster\t44620\tAll Valid: Forecast Test\t44621\t44621\tRecommended based on interval\t\t4.4\n2022-UC-0008\tPatient is an adult with Hodgkin's disease and has been administered two doses of the Zoster vaccine\t37669\tM\t180\tHodgkin's disease\t\t\t\t\t\t\t\tComplete\t44620\tZoster Recombinant\t187\tSKB\tValid\trisk\t\t44679\tZoster Recombinant\t187\tSKB\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tZoster\t44679\tAll Valid: Forecast Test\t44621\t44621\tNot Recommended: Series Complete\t\t4.4\n2022-UC-0009\tPatient is an adult undergoing radiation therapy and has been administered two doses of the Janssen Covid-19 vaccine\t30270\tF\t159\tRadiation Therapy\t\t\t\t\t\t\t\tNot Complete\t44497\tSARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL\t212\tJSN\tValid\trisk\t\t44562\tSARS-COV-2 (COVID) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL (212)\t212\tJSN\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t44618\t44618\t\tMany recipients of Janssen COVID-19 Vaccine may have already received a booster dose or Janssen vaccine), without having had the 2nd (additional) mRNA vaccine dose.  In this situation, regardless of type and timing of vaccine received as the 2nd dose, administered a Pfizer-BioNTech vaccine or a Moderna vaccine (100 mcg [0.5 mL] as the 3rd dose at least 2 months after dose 2.\tCOVID-19\t44815\tAll Valid: Forecast Test\t44815\t44815\tRecommended based on interval\t\t4.4\n2022-UC-0010\tPatient is an adult that is a receipt of CAR-T cell Therapy and has received one dose of the Janssen Covid-19 vaccine and one dose of the Pfizer vaccine\t32669\tM\t191\tReceipt of CAR-T-cell therapy\t\t\t\t\t\t\t\tNot Complete\t44462\tSARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL\t212\tJSN\tValid\trisk\t\t44531\tCOVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL\t208\tPFR\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t44587\t44587\t\tMany recipients of Janssen COVID-19 Vaccine may have already received a booster dose or Janssen vaccine), without having had the 2nd (additional) mRNA vaccine dose.  In this situation, regardless of type and timing of vaccine received as the 2nd dose, administered a Pfizer-BioNTech vaccine or a Moderna vaccine (100 mcg [0.5 mL] as the 3rd dose at least 2 months after dose 2.\tCOVID-19\t44598\tAll Valid: Forecast Test\t44608\t44608\tRecommended based on interval\t\t4.4\n2022-UC-0011\tPatient is an adult that is receiving active treatment for hematologic malignancies and has received one dose of the Janssen Covid-19 vaccine, one dose of the Moderna Covid-19 vaccine, and one dose of the Pfizer Covid-19 vaccine.\t28993\tF\t190\tActive treatement for hematologic malignancies\t\t\t\t\t\t\t\tNot Complete\t44382\tSARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL\t212\tJSN\tValid\trisk\t\t44449\tCOVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL\t207\tMOD\tValid\trisk\t\t44598\tCOVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL\t208\tPFR\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t4\t44654\t44654\t\t\tCOVID-19\t44812\tAll Valid: Forecast Test\t44815\t44815\tRecommended based on interval\t\t4.4\n2022-UC-0012\tPatient is an adult that is receiving active treatment for hematologic malignancies and has received one dose of the Janssen Covid-19 vaccine, one dose of the Moderna Covid-19 vaccine, and two doses of the Pfizer Covid-19  vaccine.\t28993\tF\t190\tActive treatement for hematologic malignancies\t\t\t\t\t\t\t\tNot Complete\t44382\tSARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL\t212\tJSN\tValid\trisk\t\t44449\tCOVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL\t207\tMOD\tValid\trisk\t\t44598\tCOVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL\t208\tPFR\tValid\tRisk\t\t44718\tCOVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL\t208\tPFR\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t5\t44774\t44774\t\t\tCOVID-19\t44814\tAll Valid: Forecast Test\t44815\t44815\tRecommended based on interval\t\t4.4\n2022-UC-0013\tPatient is an adolescent and a transplant recipient and has received five doses of a Covid-19 vaccine\t39888\tF\t157\tTransplantation\t43493\t\t\t\t\t\t\tNot Complete\t44336\tCOVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose \t208\tPFR\tValid\trisk\t\t44357\tCOVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose \t208\tPFR\tValid\trisk\t\t44573\tCOVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL\t208\tPFR\tValid\tRisk\t\t44604\tCOVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL\t208\tPFR\tValid\trisk\t\t44816\tCOVID-19, mRNA, LNP-S, bivalent booster, PF, 30 mcg/0.3 mL dose\t300\tPFR\tValid\tRisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t6\t44872\t44872\t\t\tCOVID-19\t44816\tAll Valid: Forecast Test\t44824\t44824\tRecommended based on interval\t\t4.4\n2022-UC-0014\tPatient is an adult with HIV/AIDS and is severely immunocompromised and has received five doses of a COVID-19 vaccine.\t30042\tM\t154\tHIV/AIDS - severely immunocompromised\t\t\t\t\t\t\t\tNot Complete\t44329\tCOVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL dose\t207\tMOD\tValid\trisk\t\t44357\tCOVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL\t207\tMOD\tValid\trisk\t\t44424\tCOVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL\t207\tMOD\tValid\tRisk\t\t44577\tCOVID-19, mRNA, LNP-S, PF, 100 mcg/0.5 mL or 50 mcg/.25mL\t207\tMOD\tValid\trisk\t\t44697\tCOVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL\t221\tMOD\tValid\tRisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t6\t44753\t44753\t\t\tCOVID-19\t44816\tAll Valid: Forecast Test\t44816\t44816\tRecommended based on interval\t\t4.4\n2022-UC-0015\tPatient is an adult with Leukemia and has received a PCV20 vaccine for a third dose instead of a PPSV23\t26353\tM\t178\tLeukemia\t\t\t\t\t\t\t\tComplete\t42174\tPREVNAR 13\t133\tPFR\tValid\trisk\t\t42574\tPNEUMOVAX 23 \t33\tMSD\tValid\trisk\t\t44621\tPREVNAR 20\t216\tPFR\tValid\tRisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\tAdults who have received PCV13 but have not completed their recommended pneumococcal vaccine series with PPSV23, one dose of PCV20 may be used if PPSV23 is not available.\tPneumococcal\t44621\tAll Valid: Forecast Test\t44637\t44637\tNot Recommended: Series Complete\t\t4.4\n2022-UC-0016\tPatient is an adult with Lymphoma and has received three doses of the Pneumococcal vaccine.\t35130\tM\t179\tLymphoma\t\t\t\t\t\t\t\tComplete\t42500\tPNEUMOVAX 23\t33\tMSD\tValid\trisk\t\t42917\tPREVNAR 13\t133\tPFR\tValid\trisk\t\t44747\tPREVNAR 20\t216\tPFR\tValid\tRisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\tAdults who have received PCV13 but have not completed their recommended pneumococcal vaccine series with PPSV23, one dose of PCV20 may be used if PPSV23 is not available.\tPneumococcal\t44747\tAll Valid: Forecast Test\t44637\t\tNot Recommended: Series Complete\t\t4.4\n2022-UC-0017\tPatient is an adult with diabetes and has received a PCV 15 vaccine.\t32798\tF\t014\tDiabetes\t\t\t\t\t\t\t\tNot Complete\t44585\tPCV\t215\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t44641\t44950\t\t\tPneumococcal\t44585\tAll Valid: Forecast Test\t44642\t\tRecommended based on interval\t\t4.4\n2022-UC-0018\tPatient is adult with diabetes and has received a dose of the PCV 15  and a dose of the PPSV23 vaccine.\t32798\tF\t014\tDiabetes\t\t\t\t\t\t\t\tComplete\t44585\tPCV\t215\tMSD\tValid\trisk\t\t44642\tPPSV 23\t33\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tPneumococcal\t44642\tAll Valid: Forecast Test\t44642\t\tNot Recommended: Series Complete\t\t4.4\n2022-UC-0019\tPatient is a 65 year old with multiple myeloma and has received a dose of PPSV23 and PCV15\t20191\tM\t181\tMultiple Myeloma\t\t\t\t\t\t\t\tComplete\t44209\tPNEUMOVAX 23\t33\tMSD\tValid\trisk\t\t44630\tPCV 15\t215\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tPneumococcal\t44630\tAll Valid: Forecast Test\t44642\t\tNot Recommended: Series Complete\t\t4.4\n2022-UC-0020\tPatient is a healthcare worker involved in the care and or transport of suspect or confirmed EVD at Special Pathogens Treatment Centers (SPTC) and has receive a dose of the  Ebola vaccine.\t32794\tF\t212\tHealth care personnel involved in the care and transport of patients with suspected or confirmed Ebola virus disease at Special Pathogen Treatement Centers\t\t\t\t\t\t\t\tComplete\t44652\tEbola Zaire vaccine, live\t204\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tEbola\t44652\tAll Valid: Forecast Test\t44637\t\tNot Recommended: Series Complete\t\t4.4\n2022-UC-0021\tPatient is a person whose activities bring them into frequent contact with rabies virus or potentially rabid animals and has not been administered a dose of the Rabies vaccine\t31976\tF\t062\tPersons whose activities bring theminto frequent contact with rabies virus or potentially rabid animals\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t31976\t31976\t\t\tRabies\t44678\tNo Doses Administered\t44715\t\tRecommended based on Condition\t\t4.4\n2022-UC-0022\tPatient is a person whose activities bring them into frequent contact with rabies virus or potentially rabid animals and has been administered the first dose (before 05/06/2022) of the Risk infrequent exposure Rabies vaccine. \t31976\tF\t062\tPersons whose activities bring theminto frequent contact with rabies virus or potentially rabid animals\t\t\t\t\t\t\t\tNot Complete\t44678\tRabies-IM firbroblast culture\t176\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t44685\t44685\t\t\tRabies\t44678\tAll Valid: Forecast Test\t44718\t\tRecommended based on Condition\t\t4.4\n2022-UC-0023\tPatient is a person who interacts with animals that could be rabid and has been administered a first dose of the Rabies vaccine before 05/6/022 and a second dose after 05/06/2022\t31976\tF\t062\tPersons whose activities bring theminto frequent contact with rabies virus or potentially rabid animals\t\t\t\t\t\t\t\tNot Complete\t44678\tRabies-IM firbroblast culture\t176\tPMC\tValid\trisk\t\t44691\tRabies-IM firbroblast culture\t176\t\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t44712\t44712\t45786\t\tRabies\t44691\tAll Valid: Forecast Test\t44718\t\tRecommended based on interval\t\t4.4\n2022-UC-0024\tPatient is a person who interacts with animals that could be rabid has been administered three (first dose before 05/06/2022, second and third doses after 05/06/2022) doses of the Risk infrequent exposure Rabies vaccine\t31976\tF\t062\tPersons whose activities bring theminto frequent contact with rabies virus or potentially rabid animals\t\t\t\t\t\t\t\tComplete\t44678\tRabies-IM firbroblast culture\t176\tPMC\tValid\trisk\t\t44691\tRabies-IM firbroblast culture\t176\tPMC\tValid\trisk\t\t44712\t\t176\tPMC\tValid\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tRabies\t44712\tAll Valid: Forecast Test\t44718\t\tNot Recommended: Series Complete\t\t4.4\n2022-0025\tPatient is a healthcare worker who administers ACAM2000 vaccine but has a history of atopic dermatis\t29984\tM\t239\tHealthcare personnel who administers ACAM2000\t\t224\tHistory or presence of atopic dermatitis\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t36558\t36558\t\tPersons who previously received ACAM2000 should decide before their next booster dose whether to receive ACAM2000 or JYNNEOS. Persons who transition to receiving JYNNEOS boosters are expected to continue receiving JYNNEOS boosters and to not revert to ACAM2000.\tVaccinia\t44720\tNo Doses Administered\t44720\t\tRecommended based on interval\t\t4.4\n2022-0026\tPatient is a healthcare worker who administers ACAM2000 vaccine and has had a severe allergic reaction after previous dose of a vaccinia vaccine\t33931\tF\t239\tHealthcare personnel who administers ACAM2000\t\t223\tSevere allergic reaction after previous dose of orthopoxvirus vaccine\t\t\t\t\tContraindicated\t44348\tvaccinia - smallpox \t75\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tVaccinia\t44348\tAll Valid: Forecast Test\t44720\t\tNot recommended: contraindication\t\t4.4\n2022-0027\tPatient is a clinical laboratory personnel worker performing diagnostic testing for less virulent orthopoxiviruses (e.g., Vaccinia virus or Cowpox virus) and has not been administered a dose of the Orxthopox vaccine\t31233\tM\t237\tClinical laboratory personnel performing diagnostic testing for less virulent othropoxviruses (e.g., Vaccinia virus or Cowpox viurs)\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t37807\t37807\t\tPersons who previously received ACAM2000 should decide before their next booster dose whether to receive ACAM2000 or JYNNEOS.  Persons who tranition to receiving JYNNEO boosters are expected to continue receiving JYNNEOS boosters and to not revert to ACAM2000\tVaccinia\t44507\tNo Doses Administered\t44720\t\tRecommended based on Condition\t\t4.4\n2022-0028\tPatient is a research laboratory personnel worker working with more virulent orthopoxes and has previously been administered a dose of Orthopox ACAM2000 vaccine.\t32640\tF\t232\tResearch laboratory personnel working with more virulent orthopoxviruses (e.g., Variola virus or Monekypox virus)\t\t\t\t\t\t\t\tNot Complete\t43963\tvaccinia - smallpox \t75\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t44693\t44693\t45057\tPersons who previously received ACAM2000 should decide before their next booster dose whether to receive ACAM2000 or JYNNEOS.  Persons who tranition to receiving JYNNEO boosters are expected to continue receiving JYNNEOS boosters and to not revert to ACAM2000; in addition, the frequency of booster doses should correspond to the vaccine used for boosters. For example, persons who previously received ACAM2000 every 3 years because of work with more virulent orthopoxviruses might decide to change to JYNNEOS when their next booster is due; in these cases, subsequent JYNNEOS booster doses should be administered every 2 years. \tVaccinia\t43963\tAll Valid: Forecast Test\t44720\t\tRecommended based on interval\t\t4.4\n2022-0029\tPatient is a research laboratory personnel worker working with more virulent orthopoxvirus and has  been administered ACAM2000 as a primary and booster dose.\t32640\tF\t232\tResearch laboratory personnel working with more virulent orthopoxviruses (e.g., Variola virus or Monekypox virus)\t\t\t\t\t\t\t\tNot Complete\t43963\tvaccinia - smallpox \t75\tPMC\tValid\trisk\t\t44693\t\t75\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t45424\t45424\t45788\tPersons who previously received ACAM2000 should decide before their next booster dose whether to receive ACAM2000 or JYNNEOS.  Persons who tranition to receiving JYNNEO boosters are expected to continue receiving JYNNEOS boosters and to not revert to ACAM2000; in addition, the frequency of booster doses should correspond to the vaccine used for boosters. For example, persons who previously received ACAM2000 every 3 years because of work with more virulent orthopoxviruses might decide to change to JYNNEOS when their next booster is due; in these cases, subsequent JYNNEOS booster doses should be administered every 2 years. \tVaccinia\t44693\tAll Valid: Forecast Test\t44720\t\tRecommended based on interval\t\t4.4\n2022-0030\tPatient is a healthcare personnel worker who cares for patients infected with a more virulent orthopoxvirus and has been administered a dose of the Orthopoxirus (Jynneos) vaccine.\t25495\tM\t235\tHealthcare personnel who cares for patients infected with more virulent orthopoxvirues (e.g., Variola virus or Monkeypox virus)\t\t\t\t\t\t\t\tNot Complete\t44715\tvaccinia - smallpox \t206\tBN\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t44743\t44743\t\tPersons who previously received ACAM2000 should decide before their next booster dose whether to receive ACAM2000 or JYNNEOS.  Persons who tranition to receiving JYNNEO boosters are expected to continue receiving JYNNEOS boosters and to not revert to ACAM2000; in addition, the frequency of booster doses should correspond to the vaccine used for boosters. For example, persons who previously received ACAM2000 every 3 years because of work with more virulent orthopoxviruses might decide to change to JYNNEOS when their next booster is due; in these cases, subsequent JYNNEOS booster doses should be administered every 2 years. \tVaccinia\t44715\tAll Valid: Forecast Test\t44720\t\tRecommended based on interval\t\t4.4\n2022-0031\tPatient is a healthcare personnel worker who cares for patients infected with a more virulent orthopoxvirus and has been administered the second dose of the Orthopoxirus (Jynneos) vaccine.\t25495\tM\t235\tHealthcare personnel who cares for patients infected with more virulent orthopoxvirues (e.g., Variola virus or Monkeypox virus)\t\t\t\t\t\t\t\tNot Complete\t44715\tvaccinia - smallpox \t206\tBN\tValid\trisk\t\t44743\tVaccinia-smallpox\t206\tBN\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t45474\t45474\t45838\tPersons who previously received ACAM2000 should decide before their next booster dose whether to receive ACAM2000 or JYNNEOS.  Persons who tranition to receiving JYNNEO boosters are expected to continue receiving JYNNEOS boosters and to not revert to ACAM2000; in addition, the frequency of booster doses should correspond to the vaccine used for boosters. For example, persons who previously received ACAM2000 every 3 years because of work with more virulent orthopoxviruses might decide to change to JYNNEOS when their next booster is due; in these cases, subsequent JYNNEOS booster doses should be administered every 2 years. \tVaccinia\t44743\tAll Valid: Forecast Test\t44720\t\tRecommended based on interval\t\t4.4\n2022-0032\tPatient is a healthcare personnel worker who administers ACAM2000  and has been administered a dose of the ACAM2000 Orxthopoxvirus vaccine.\t30438\tF\t239\tHealthcare personel who administers ACAM2000\t\t\t\t\t\t\t\tNot Complete\t43932\tvaccinia - smallpox \t75\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t47584\t47584\t\tPersons who previously received ACAM2000 should decide before their next booster dose whether to receive ACAM2000 or JYNNEOS.  Persons who tranition to receiving JYNNEO boosters are expected to continue receiving JYNNEOS boosters and to not revert to ACAM2000\tVaccinia\t43932\tAll Valid: Forecast Test\t44721\t\tRecommended based on Condition\t\t4.4\n2022-0033\tPatient is a designated response team member working with more virulent orthopoxivirus (e.g. Variola birus or Monkeypox virus)and has received the ACAM2000 Orxthopox vaccine. \t28829\tF\t234\tDesignated response team members working with more virulent orthopoxviruses (e.g., Variola virus or Monkeypox virus)\t\t\t\t\t\t\t\tNot Complete\t43995\tvaccinia - smallpox \t75\tPMC\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t44725\t44725\t45089\tBooster doses are recommended for response personnel only once an event is identified.  Persons who previously received ACAM2000 should decide before their next booster dose whether to receive ACAM2000 or JYNNEOS.  Persons who tranition to receiving JYNNEO boosters are expected to continue receiving JYNNEOS boosters and to not revert to ACAM2000; in addition, the frequency of booster doses should correspond to the vaccine used for boosters. For example, persons who previously received ACAM2000 every 3 years because of work with more virulent orthopoxviruses might decide to change to JYNNEOS when their next booster is due; in these cases, subsequent JYNNEOS booster doses should be administered every 2 years. \tVaccinia\t43995\tAll Valid: Forecast Test\t44721\t\tRecommended based on interval\t\t4.4\n2022-0034\tPatient is a designated response team member working with more virulent orthopoxivirus (e.g. Variola birus or Monkeypox virus)and has received the ACAM2000 Orxthopox vaccine and a booster dose of the Jynneos Orthopox vaccine\t28829\tF\t234\tDesignated response team members working with more virulent orthopoxviruses (e.g., Variola virus or Monkeypox virus)\t\t\t\t\t\t\t\tNot Complete\t43995\tvaccinia - smallpox \t75\tPMC\tValid\trisk\t\t44725\tVaccinia-smallpox\t206\tBN\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t45456\t45456\t45820\tBooster doses are recommended for response personnel only once an event is identified.  Persons who previously received ACAM2000 should decide before their next booster dose whether to receive ACAM2000 or JYNNEOS.  Persons who tranition to receiving JYNNEO boosters are expected to continue receiving JYNNEOS boosters and to not revert to ACAM2000; in addition, the frequency of booster doses should correspond to the vaccine used for boosters. For example, persons who previously received ACAM2000 every 3 years because of work with more virulent orthopoxviruses might decide to change to JYNNEOS when their next booster is due; in these cases, subsequent JYNNEOS booster doses should be administered every 2 years. \tVaccinia\t44725\tAll Valid: Forecast Test\t44721\t\tRecommended based on interval\t\t4.4\n2022-0035\tPatient is a clinical laboratory worker working with less virulent orthopoxivirus and has received two doses of the Orthopox vaccine\t31233\tM\t237\tClinical laboratory personnel performing diagnostic testing for less virulent othropoxviruses (e.g., Vaccinia virus or Cowpox viurs)\t\t\t\t\t\t\t\tNot Complete\t44507\tvaccinia - smallpox \t206\tBN\tValid\trisk\t\t44698\tVaccinia-smallpox\t206\tBN\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t48351\t48351\t\t\tVaccinia\t44698\tAll Valid: Forecast Test\t44839\t\tRecommended based on Condition\t\t4.4\n2022-0036\tPatient is 16 months of age and is receiving active treatment for solid tumors and has not received a dose of a COVID-19 vaccine.\t44289\tF\t189\tActive treatement for solid tumors\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t44472\t44472\t\tCovid-19 vaccines and other vaccines may now be administered without regard to timing.  This includes simultaneous adminstration of Covid-19 vaccines and other vaccines on the same day.  People, particulary adolescent or young male adults, might consider waiting 4 weeks after orthopxvirus vaccination.\tCOVID-19\t44776\tAll Valid: Forecast Test\t44839\t\tRecommended based on Condition\t\t4.4\n2022-0037\tPatient is 16 months of age and is receiving active treatment for solid tumors and has received the first dose of the Pfizer COVID-19 vaccine\t44289\tF\t189\tActive treatement for solid tumors\t\t\t\t\t\t\t\tNot Complete\t44776\tCOVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose \t219\tPFR\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t44797\t44797\t\tCovid-19 vaccines and other vaccines may now be administered without regard to timing.  This includes simultaneous adminstration of Covid-19 vaccines and other vaccines on the same day.  People, particulary adolescent or young male adults, might consider waiting 4 weeks after orthopxvirus vaccination.\tCOVID-19\t44776\tAll Valid: Forecast Test\t44839\t\tRecommended based on interval\t\t4.4\n2022-0038\tPatient is 16 months and is receiving active treatment for solid tumors and has received the second dose of the Pfizer COVID-19 vaccine.\t44289\tF\t189\tActive treatement for solid tumors\t\t\t\t\t\t\t\tNot Complete\t44776\tCOVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose \t219\tPFR\tValid\trisk\t\t44797\tCOVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose \t219\tPFR\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t44825\t44825\t\tCovid-19 vaccines and other vaccines may now be administered without regard to timing.  This includes simultaneous adminstration of Covid-19 vaccines and other vaccines on the same day.  People, particulary adolescent or young male adults, might consider \tCOVID-19\t44797\tAll Valid: Forecast Test\t44860\t\tRecommended based on interval\t\t4.4\n2022-0039\tPatient is 16 months and is receiving active treatment for solid tumors and has received three doses of the Pfizer COVID-19 vaccine. \t44289\tF\t189\tActive treatement for solid tumors\t\t\t\t\t\t\t\tComplete\t44776\tCOVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose \t219\tPFR\tValid\trisk\t\t44797\tCOVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose \t219\tPFR\tValid\trisk\t\t44853\tCOVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose \t219\tPFR\tValid\tRisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\tCovid-19 vaccines and other vaccines may now be administered without regard to timing.  This includes simultaneous adminstration of Covid-19 vaccines and other vaccines on the same day.  People, particulary adolescent or young male adults, might consider \tCOVID-19\t44853\tAll Valid: Forecast Test\t44860\t\tNot Recommended: Series Complete\t\t4.4\n2022-0040\tPatient is 26 years and has HIV and has been administered the first dose of the Novavax vaccine\t35170\tM\t154\tHIV/AIDS - Severely immunocompromised\t\t\t\t\t\t\t\tNot Complete\t44757\tCOVID-19 vaccine, Subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL\t211\tNOV\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t44778\t44778\t\t\tCOVID-19\t44757\tAll Valid: Forecast Test\t44860\t\tRecommended based on interval\t\t4.4\n2022-0041\tPatient is 26 years and has HIV and has been administered the second dose of the Novavax vaccine\t35170\tM\t154\tHIV/AIDS - Severely immunocompromised\t\t\t\t\t\t\t\tNot Complete\t44757\tCOVID-19 vaccine, Subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL\t211\tNOV\tValid\trisk\t\t44778\tCOVID-19 vaccine, Subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL\t211\tNOV\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t44834\t44834\t\tPeople ages 18 years and older who completed primary vaccination using any COVID-19 vaccine and have not received any previous booster dose(s) may receive a monovalent Novavax booster dose at least 6 months after completion of the primary series if they are unable to receive an mRNA vaccine (i.e., mRNA vaccine contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose.\tCOVID-19\t44778\tAll Valid: Forecast Test\t44861\t\tRecommended based on interval\t\t4.4\n2022-0042\tPatient is 26 years and has HIV and has been administered  two doses of the Novavax vaccine and one dose of the Bivalent Covid-19 vaccine.\t35170\tM\t154\tHIV/AIDS - severely immunocompromised\t\t\t\t\t\t\t\tComplete\t44757\tCOVID-19 vaccine, Subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL\t211\tNOV\tValid\trisk\t\t44778\tCOVID-19 vaccine, Subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL\t211\tNOV\tValid\trisk\t\t44834\tCOVID-19, mRNA, LNP-S, bivalent booster, PF, 30 mcg/0.3 mL dose\t300\tPFR\tValid\tRisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tCOVID-19\t44834\tAll Valid: Forecast Test\t44861\t\tNot Recommended: Series Complete\t\t4.4\n2022-0043\tPatient is 37 years of age and has a known exposure to Monkeypox but has not been administered any doses of the Orthopoxvirus vaccine\t31291\tF\t241\tKnown exposure to monkeypox\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t31291\t31472\t\t\tVaccinia\t44814\tNo Doses Administered\t44866\t\tRecommended based on Condition\t\t4.4\n2022-0044\tPatient is 37 years of age and has a known exposure to Monkeypox and has been administered the first  doses of the Jynneos Orthopoxvirus vaccine\t31291\tF\t241\tKnown exposure to monkeypox\t\t\t\t\t\t\t\tNot Complete\t44814\tvaccinia - smallpox monkeypox vaccine live, PF\t206\tBN\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t44842\t44842\t\t\tVaccinia\t44814\tAll Valid: Forecast Test\t44866\t\tRecommended based on interval\t\t4.4\n2022-0045\tPatient is 37 years of age and has a known exposure to Monkeypox and has been administered a second dose of the Jynneos vaccine.\t31291\tF\t241\tKnown exposure to monkeypox\t\t\t\t\t\t\t\tComplete\t44814\tvaccinia - smallpox monkeypox vaccine live, PF\t206\tBN\tValid\trisk\t\t44842\tvaccinia - smallpox monkeypox vaccine live, PF\t206\tBN\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t-\t\t\t\t\tVaccinia\t44842\tAll Valid: Forecast Test\t44866\t\tNot Recommended: Series Complete\t\t4.4\n2022-0046\tPatient is 3 years of age and has B-lymphocyte [humoral] - Severe antibody deficiencies (145) and has not received any doses of Pneumo\t43667\tM\t145\tB-lymphocyte [humoral] - Severe antibody deficiencies\t\t\t\t\t\t\t\tNot Complete\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1\t44398\t44398\t\t\tPneumococcal\t44824\tNo Doses Administered\t44872\t\tRecommended based on Condition\t\t4.4\n2022-0047\tPatient is 3 years of age and has B-lymphocyte [humoral] - Severe antibody deficiencies (145) and has been administered the first dose of the Pneumococcal vaccine.\t43667\tM\t145\tB-lymphocyte [humoral] - Severe antibody deficiencies\t\t\t\t\t\t\t\tNot Complete\t44824\tPCV15\t215\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t2\t44880\t44880\t\t\tPneumococcal\t44824\tAll Valid: Forecast Test\t44872\t\tRecommended based on interval\t\t4.4\n2022-0048\tPatient is 3 years of age and has B-lymphocyte [humoral] - Severe antibody deficiencies (145) and has been administered the second dose of the Pneumococcal vaccine.\t43667\tM\t145\tB-lymphocyte [humoral] - Severe antibody deficiencies\t\t\t\t\t\t\t\tNot Complete\t44824\tPCV15\t215\tMSD\tValid\trisk\t\t44880\tPCV15\t215\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t3\t44936\t44936\t\t\tPneumococcal\t44880\tAll Valid: Forecast Test\t44872\t\tRecommended based on interval\t\t4.4\n2022-0049\tPatient is 3 years of age and has B-lymphocyte [humoral] - Severe antibody deficiencies (145) and has been administered the third dose of the Pneumococcal vaccine.\t43667\tM\t145\tB-lymphocyte [humoral] - Severe antibody deficiencies\t\t\t\t\t\t\t\tNot Complete\t44824\tPCV15\t215\tMSD\tValid\trisk\t\t44880\tPCV15\t215\tMSD\tValid\trisk\t\t44936\tPPSV 23\t33\tMSD\tValid\trisk\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t4\t46762\t46762\t\t\tPneumococcal\t44936\tAll Valid: Forecast Test\t44872\t\tRecommended based on Condition\t\t4.4\n"}]